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 ABSTRACT 
A plethora of databases exist online that can assist in in silico chemical or drug safety 1 
assessment. However, a systematic review and grouping of databases, based on purpose and 2 
information content, consolidated in a single source, has been lacking. To resolve this issue, 3 
this review provides a comprehensive listing of the key in silico data resources relevant to: 4 
chemical identity and properties, drug action, toxicology (including nano-material toxicity), 5 
exposure, omics, pathways, Absorption, Distribution, Metabolism and Elimination (ADME) 6 
properties, clinical trials, pharmacovigilance, patents-related databases, biological (genes, 7 
enzymes, proteins, other macromolecules etc.) databases, protein-protein interactions (PPIs), 8 
environmental exposure related, and finally databases relating to animal alternatives in 9 
support of 3Rs policies. More than nine hundred databases were identified and reviewed 10 
against criteria relating to accessibility, data coverage, interoperability or application 11 
programming interface (API), appropriate identifiers, types of in vitro, in vivo¸-clinical or other 12 
data recorded and suitability for modelling, read-across or similarity searching. This review 13 
also specifically addresses the need for solutions for mapping and integration of databases 14 
into a common platform for better translatability of preclinical data to clinical data. 15 
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1. Introduction 
 
Chemical risk assessment refers to the quantification of any potential adverse effects to 18 
humans or environmental species related to exposure to chemicals, drugs, pesticides, 19 
consumer products or any other substances. Traditionally, the assessment of chemicals, 20 
including pharmaceuticals, relied on data from animal testing; however, there are many 21 
motivations to move to a society free of such testing. In part, the new paradigm for safety 22 
assessment embraces the ethos of 21st Century Toxicology whereby every effort is made to 23 
maximise the information that may be obtained without animal testing (Embry et al., 2014). 24 
This information may include existing knowledge on the chemical in question, or similar 25 
chemicals (the process of read-across), as well as in vitro and high throughput determination 26 
relating to mechanisms of action and effects at the cellular or organ level (Cronin et al., 2009; 27 
Kongsbak et al., 2014). Existing and experimental data are also supplemented by predictions, 28 
which may relate to toxicity, mechanisms or exposure that are collectively termed “in silico”. 29 
There is no formal definition for the process or practice of in silico chemical safety assessment; 30 
however, it needs to encompass existing knowledge and outputs from predictions of both 31 
hazard and exposure as a means of making a decision. There is also increasing interest in 32 
making this type of information gathering and assessment more translational, to gain 33 
knowledge from all sources to understand the effects on humans – patients in the case of 34 
pharmaceuticals – and how that can be translated to mechanisms and assays etc.  35 
There are various types of data that may be considered in modern in silico chemical safety 36 
assessment. Historical, or legacy, data from toxicological testing provide one of the most 37 
important sources of information for modelling and read-across. In theory, data should be 38 
available for all endpoints that have been tested across a variety of guideline and non-39 
standard approaches. Such data may be either available openly or be confidential business 40 
information and may encompass toxicological and physico-chemical information. Such data 41 
have been the cornerstone of in silico modelling in the past and remain essential for 42 
performing safety assessment of existing chemicals. At the other end of the spectrum are 43 
upcoming resources that capture mechanistic understanding of chemicals. Such 44 
understanding has, in part at least, been facilitated by the so-called “New Approach 45 
Methodologies” (NAMs) including in vitro High-Throughput Screening (HTS) methods 46 
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(bioactivity or toxicity profiling bioassays) and omics data generated by more specific genome 47 
sequencing, transcriptomics, proteomics and metabolomics studies (Hartung et al., 2017). 48 
These, and other large data repositories, such as clinical effects and adverse drug reactions 49 
are routinely referred to as being big data. The term “big data” implies a huge volume of data 50 
collected from multiple resources and characterised by their complexity and heterogenous 51 
nature. Computational tools often manage big data or algorithms that help to capture, store, 52 
search and analyse the data more rapidly.   53 
Capturing a chemical’s physico-chemical properties, bioactivity and safety profiles or toxicity 54 
within databases has become a necessary part of research across many industrial sectors 55 
including pharmaceuticals, personal care products, petro-chemicals and biocides. As a result, 56 
in silico resources have been reviewed and assessed previously by many researchers, as 57 
indicated in Table 1, which identifies 48 of these recent reviews. For example,  Young et al., 58 
(Young, 2002) reviewed web-based resources at the US National Library of Medicine (NLM) 59 
including MEDLINE®, PUBMED®, Gateway, Entrez and TOXNET. As systems biology emerged 60 
many gene expression repositories and software were also developed (Anderle et al., 61 
2003;Judson, 2010;Benigni et al., 2013;Fostel et al., 2014). Efforts were not limited to only 62 
gene or protein expression databases, but also included organ specific toxicity databases. The 63 
review by Fotis et al., 2018 (Fotis et al., 2018) discussed databases relating to genomics, 64 
proteomics, metabolomics, multiomics whilst the review by Papadopoulos et al., 2016 65 
(Papadopoulos et al., 2016) focused on such databases specifically relating to the kidney. In 66 
relation to other major organs, liver and heart-related toxicity databases have been discussed 67 
by Luo et al., 2017 (Luo et al., 2017) and Sato et al., 2018 (Sato et al., 2018) respectively. These 68 
diverse types of databases have been further expanded or designed in such a way as to enable 69 
interaction with other public resources so improving accessibility for end users. Many 70 
resources have emerged that try to link or integrate the chemistry-based databases with 71 
bioactivity, pathways of toxicity, ADME and omics data sets. The chemistry-based databases 72 
on small molecules or new compounds were discussed in detail in a number of reviews 73 
(Jonsdottir et al., 2005;Williams, 2008;Hersey et al., 2015). Some of the databases that allow 74 
for mining of the chemical information (such as 2D, 3D structures, physico-chemical 75 
properties etc.) are ChEMBL, ChEBI, PubChem, DrugBank, ZINC, etc. In drug discovery, the 76 
number of databases for target identification or prediction of activity, has grown 77 
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tremendously (Oprea and Tropsha, 2006;Loging et al., 2011;Chen and Butte, 2016;Chen et al., 78 
2016;Katsila et al., 2016;Cha et al., 2018). Other databases containing information on proteins 79 
associated with drug therapeutic effects, adverse drug reactions and ADME properties has 80 
facilitated systematic curation and analysis of complex ligand-target data (Ji et al., 2003a). 81 
Some of the ADME, potential drug-drug interaction (DDI) information and 82 
pharmacogenomics-related databases have been cited in a number of review articles (Ekins 83 
et al., 2005;Bauer-Mehren et al., 2009;Ekins and Williams, 2010;Sim et al., 2011;L Peach et 84 
al., 2012;Wishart, 2014;Ayvaz et al., 2015;Zhang et al., 2015;Przybylak et al., 2018). Fouretier 85 
2016 (Fouretier et al., 2016) identified human drug safety data resources, or 86 
pharmacovigilance databases, specific to every country or subcontinent. The European 87 
Union’s Innovative Medicines Initiative 2 Joint Undertaking (IMI 2) “Enhancing TRANslational 88 
SAFEty Assessment through Integrative Knowledge Management (eTRANSAFE)” project is 89 
developing an integrative data infrastructure to combine and utilise data resources, hence 90 
has stimulated the work described in this paper. The aim of eTRANSAFE is to drastically 91 
improve the feasibility and reliability of translational safety assessment during the drug 92 
development process using both publicly available resources in addition to data provided by 93 
its partners to facilitate acceptance by stakeholders, including regulatory agencies and 94 
international organisations. 95 
In spite of many previous reviews of data sources for specific types of data (chemistry based, 96 
toxicology, omics, ADME etc.), or those predominantly focussed on a specific type of data, no 97 
review exists covering all data resources that may be required for 21st Century Toxicology and 98 
translational sciences in drug discovery. Moreover, many reviews have failed to address the 99 
importance of the full identification, mapping and integration of chemical and biological 100 
spaces. Thus, the aim of this study was to provide a comprehensive and consolidated list of in 101 
silico data resources for chemical safety assessment. This review aimed to encompass all data 102 
resources including those based on chemistry, pharmacological space, genomics and adverse 103 
events, as well as those relevant to toxicology and human effects or clinical safety studies. 104 
The databases were assessed in groups based on their purpose and information content; data 105 
relating to each resource was recorded and summarised. It is intended that this review will 106 
provide a valuable starting point for researchers wishing to gain knowledge about a chemical 107 
substance and its exposure/effect in preclinical and clinical studies.  108 
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2. Methods  
Initially, the different types of databases to be reviewed were established. The categories 109 
chosen for investigation were chemistry-based databases containing information on: 110 
toxicology (preclinical studies for chemicals and drugs), genes or enzymes, pathways or AOP-111 
related, omics, protein-protein interactions, ADME, drug discovery, clinical trials, 112 
pharmacovigilance, patent-based, environmental chemical exposure, nanomaterial toxicity 113 
and animal alternatives or 3Rs related databases. These categories were utilised to facilitate 114 
the searching and grouping/clustering of databases. An iterative process was followed to 115 
identify the multiple independent, disparate databases by searching for specific category-116 
based databases in published review papers (Table 1), regulatory-based websites (US FDA, 117 
EPA etc.), chemical/ pharmaceutical company websites and some of the specific resources on 118 
databases such as Toxnet1, Pathguide2, Fair sharing3 , VLS3D4, Wikipedia5, Oxford Journal’s 119 
biological databases6 and AltTox.org7 etc.  120 
The criteria by which the databases were assessed were established and are summarised in 121 
Table 2; the criteria stipulate both essential and desirable features. Each database was 122 
screened using these criteria and only those meeting minimum requirements are included 123 
within this review. The most important criterion on which to select a database was its ease of 124 
accessibility. The databases could be considered as “open” (free to accesss or use, right to 125 
share and re-use) or “partially open” (where only partial metadata are available to access or 126 
download or not intended for commercial use). Some of the databases for which the URL links 127 
are retired were removed from the list. The availability of information on the type of 128 
Application Programming Interface (API) or the programming codes used to develop the 129 
databases was also considered as a criterion in selecting the databases. Other essential 130 
criteria include- appropriate chemical identifiers (such as SMILES, InChIs etc.), readily 131 
                                                          
1 https://toxnet.nlm.nih.gov/ 
2 http://pathguide.org/ 
3 https://fairsharing.org/databases/ 
4 http://www.vls3d.com/ 
5 https://en.wikipedia.org/wiki/List_of_biological_databases 
6 https://www.oxfordjournals.org/nar/database/a/ 
7 http://alttox.org/resource-center/databases/ 
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converted ontologies and the relevance of the endpoint(s). The desirable attributes included 132 
access to the metadata, study protocols, information on data quality assessment, ease of 133 
navigation and other database statistics relating to the frequency of updates and number of 134 
compounds or drugs reported. Additional criteria related to the nature of the information 135 
provided or the potential use of the database and covers the type of data recorded (in vitro/ 136 
in vivo/ biomarkers/ omics/ clinical data etc.). The type of data incorporated in the database 137 
was limited not only to experimental data (in vitro, in vivo) but also included predicted data, 138 
quantitative structure-activity relationship (QSAR) models, similarity searching for chemicals 139 
or genes and read-across methods. 140 
The list of more than 900 databases is provided in Table 3 and other detailed information of 141 
each database is compiled in an Excel spreadsheet (Supplementary Information). The 142 
information included: the name of the database; the owner of the database; any licensing 143 
requirements or restrictions on use; the URL or other information on database location; 144 
access rights (e.g. registration requirement, free access, potential to download all data etc.); 145 
endpoints covered; number and type of compounds included; granularity of data (e.g. test 146 
results, dose-response data, experimental conditions etc.) and details on data quality 147 
assurance (e.g. details of curation and assignment of quality score such as Klimisch scores) 148 
where applicable. Klimisch scores (Klimisch et al., 1997) are assigned to toxicological or 149 
physico-chemical data to assess their adequacy, relevance and reliability. The scores are as 150 
follows: 1= reliable without restrictions; 2 = reliable with restrictions; 3= not reliable 4= not 151 
assignable. These scores are based on criteria such as whether the study was conducted under 152 
Good Laboratory Practice (GLP) and if key information on test substances, experimental 153 
conditions and statistical evaluation was stated.   154 
 
3. Results  
Based on the criteria established herein for selecting databases, a comprehensive list of more 155 
than 900 databases was compiled (Table 3) and consolidated. The types and relative 156 
proportion of databases identified  are summarised in Fig 2. The key features of the databases 157 
within each of the 13 groups identified are summarised below.  158 
Fig 2: Chart showing the number of databases within each group  
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(Note: DI = Drug Information, CT = Clinical trials, PV = Pharmacovigilance, PPI = Protein-protein 
interactions, Animal Alt = Animal alternatives) 
 
Chemistry databases: 80 chemistry databases were identified which relate to resources 
containing a large library of diverse chemicals or compounds with additional information 
such as name, molecular formula, structure (2D/3D), key identifiers (CAS Registry 
Number, IUPAC name, InChI, SMILES), physico-chemical properties and associations with 
their bioactivities8. Generally, such databases enable users to perform chemical similarity 
searches based on different fingerprinting methods such as MACCs, Atom pairs and 
Topological Torsion Fingerprints etc. However, despite potentially high numbers of 
compounds, many of these databases are very sparsely populated particularly with regard 
to high quality toxicity data. Such data resources do provide a useful and usable gateway 
to multiple databases such as ChEMBL, KEGG, GeneTox, Daily Med etc. 
                                                          
8  References are included in the word supplementary document section I. 
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The applicability, efficiency and diversity of any database depends on the extent of 159 
coverage of chemical space. Within the chemical databases, PubChem (Butkiewicz et 160 
al., 2017) includes the highest number of compounds (97 million compounds, 238 161 
million substances, 264 million bioactivities, 3 million patents and 633 data sources) 162 
in comparison to ChemSpider (Pence and Williams, 2010) (68 million chemical 163 
structures, 252 data sources) and ChEMBL (Gaulton et al., 2017) (1.8 million 164 
compounds and 1.1 million assays). However, the uniqueness of these chemistry-165 
based databases lies in their associations with bioactivities. For example, ChEMBL 166 
provides data on bioactive molecules (drug-like properties) and links chemical, 167 
bioactivity and genomic data. ChemSpider provides information on physical 168 
properties, biological activities (where available), interactive spectra, the name of 169 
chemical suppliers and other miscellaneous information.  170 
 
The chemistry-based databases also possess additional tools such as drawing tools, 171 
the capability to search for similar structures (both 2-D and 3-D) using similarity 172 
scorings, facilities for structure clustering, identifier exchange services, classification 173 
browsers, facilities enabling bulk download etc. For the purposes of virtual screening 174 
of compounds, building blocks or scaffolds/fragments, many databases were 175 
identified such as ZINC-15 (Sterling and Irwin, 2015), ChemSpace9, eMolecules10, 176 
Generated DataBase (GDB-DB) (Ruddigkeit et al., 2013), Biovia Screening Compounds 177 
Directory (SCD)11, Probes and drug portal etc. (Skuta et al., 2017).  Zinc-15 covers over 178 
230 million ready-to-dock compounds in 3D-formats and 750 million purchasable 179 
compounds for screening purposes. In comparison to Zinc-15, Chemspace covers 100 180 
million eMolecules 1.5 million and GDB-DB 26.4 million structures for small organic 181 
molecules. Biovia SCD contains 9.7 million unique “drug-like” chemicals for HTS and 182 
lists over 21 million individual products with prices and supplier ordering information.  183 
 
The Probes and Drugs portal is a partially open resource of bioactive compounds 184 
(probes, drugs, kinase inhibitors etc. for commercial screening purposes. It contains 185 
                                                          
9 https://chem-space.com/ 
10 https://www.emolecules.com/ 
11 http://accelrys.com/ 
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48 compound sets, 46,401 compounds, 34,887 standardised compounds, 18,612 186 
scaffolds, 6,206 targets, 4,98,201 bioactivities, 2,455 pathways, 4,174 target/pathway 187 
classes, 483 structural alerts, 2,791 and matched structural alerts. Other DBs such as 188 
ChemDB (Chen et al., 2007) and OCHEM (Sushko et al., 2011;Sushko et al., 2012) could 189 
be useful for providing a modeling framework to perform QSPR/QSAR studies online. 190 
ChemDB contains nearly 5 million small molecules and includes data on predicted or 191 
experimentally determined physicochemical properties (3D structure, melting 192 
temperature and solubility). It also includes a chemical fingerprint-based method to 193 
search for similar chemicals based on atom-bond connectivity. OCHEM contains 194 
20,56,039 records for 548 properties (physchem or ADME related) and structural 195 
alerts for endpoints such as mutagenicity, skin sensitisation, aquatic toxicity, etc. 196 
 
I. Toxicological Databases: 57 databases were identified pertaining to resources 197 
providing information on the effects of drugs or xenobiotics on cells, organs or the 198 
whole body12. Data are available of many different toxicity endpoints such as: 199 
endocrine disruption, mutagenicity, carcinogenicity, skin sensitisation, teratogenicity, 200 
organ-specific toxicity etc. Data are either derived from in vitro or in vivo studies or 201 
from in silico prediction across multiple species. Of the databases identified, a 202 
noteworthy example is the US EPA’s Aggregated Computational Toxicology Online 203 
Resource  (AcToR) (Judson et al., 2008), covering over 500,000 chemicals. It is the 204 
warehouse for many EPA’s web-based applications such as the Chemistry Dashboard 205 
(over 700,000 chemicals and includes chemical structures, experimental and 206 
predicted physicochemical and toxicity data), Toxicity Forecaster (ToxCast) Dashboard 207 
(HTS data on over 9,000 chemicals and information on approximately 1,000 assay 208 
endpoints), Endocrine Disruption Screening Program in the 21st Century Dashboard, 209 
Chemical Product Category (CPCat) and exposure databases for personal care 210 
products.        211 
 
Other significant toxicological data resources include the Gene-Tox database from the 212 
National Institutes of Health (NIH) U.S National Library of Medicine (NLM) which 213 
                                                          
12  References are included in the word supplementary document section II. 
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comprises mutagenicity data for more than 3,000 chemicals. The RepDose and FeDTex 214 
databases (Bitsch et al., 2008) are useful sources for No Observed (Adverse) Effect 215 
Level (NO(A)EL) or Lowest Observed (Adverse) Effect Level (LO(A)EL values from 216 
repeated dose studies for reproductive and developmental toxicity endpoints. 217 
RepDose consists of data on > 400 chemicals investigated in 1,018 studies resulting in 218 
6,002 specific effects. The HESS database (Sakuratani et al., 2013) contains 219 
information on 28 day repeat dose toxicity studies for 289 industrial chemicals in rats 220 
and includes  additional rat metabolism datasets and information on ADME in rats and 221 
humans.  222 
 
The list of databases also includes toxicogenomic related data sources such as the 223 
Comparative Toxicogenomics Database (CTD) (Davis et al., 2011), Open-TG Gates 224 
(Igarashi et al., 2015), The Data Infrastructure for Chemical Safety (diXa) (Hendrickx et 225 
al., 2015) , Toxygates (Nyström-Persson et al., 2013;Natsume-Kitatani et al., 2017) etc. 226 
Open-TG-GATES stores gene expression profiles and traditional toxicological data 227 
derived from in vivo (rat) and in vitro (primary rat hepatocytes, primary human 228 
hepatocytes) exposure to 170 compounds at multiple dosages and time points. 229 
Toxygates is the new interactive version of data from Open-TG-GATES covering 24,011 230 
samples and 170 compounds. The diXa database provides a one stop resource for 231 
toxicogenomics studies with cross-links to chemical and molecular medicine 232 
databases. DiXa contains data from 34 studies involving 469 compounds and recently, 233 
all the data have been migrated to the BioStudies (EMBL-EBI) platform (Sarkans et al., 234 
2018). BioStudies contains biological data or models and links them to external 235 
resources. At the time of writing it contains 2,552,605 files, 2,824,923 links, four 236 
projects and 1,214,176 studies. CTD is another valuable resource which includes more 237 
than 30.5 million toxicogenomic connections relating chemicals/drugs, 238 
genes/proteins, diseases, taxa, Gene Ontology (GO) annotations, pathways, and gene 239 
interaction modules.  240 
 
ChemTunes & ToxGPS consists of in vitro and in vivo toxicity endpoint specific alerting 241 
chemotypes; mechanism of action (MOA) based QSAR models, weight of evidence 242 
(WoE) outcomes and Tox-GPS datasets. Other organ specific toxicity databases 243 
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inlcude: AMED cardiotoxicity (Sato et al., 2018), LiverTox (Hoofnagle et al., 2013), Liver 244 
Toxicity Knowledge Base (LTKB) (Chen et al., 2011), the National Center for 245 
Toxicological Research liver cancer database (NCTRIcdb) (Beger et al., 2004) etc. The 246 
AMED cardiotoxicity database contains data on small molecules that bind to various 247 
ion channels and potentially cause cardiotoxic risk. The data on bioactivities for hERG 248 
potassium channel were collected from ChEMBL, the NIH Chemical Genomics Center 249 
and hERGCentral. They consist of 9,259 hERG inhibitors (IC50≤10µM) and 279,718 250 
inactive compounds (IC50>10µM). LiverTox is comprehensive resource on drug 251 
induced liver injury caused by prescription and non-prescription drugs, herbals and 252 
dietary supplements (1000’s of DILI agents). LTKB has been developed by the US FDA’s 253 
National Center for Toxicological Research to study drug-induced liver injury (DILI). 254 
The data are related to DILI mechanisms, drug metabolism, histopathology, 255 
therapeutic use, targets, side effects, biomarkers etc. DILIrank consists of 1,036 FDA-256 
approved drugs that are divided into four classes, Most-DILI-concern drug (192 drugs); 257 
Less-DILI-concern drug (278 drugs), No-DILI-concern drug (312 drugs) and Ambiguous-258 
DILI-concern drug (254 drugs). NCTRIcdb contains 999 chemicals classified as 273 liver 259 
carcinogen, 293 other carcinogen and 304 as non-carcinogen based on studies of male 260 
and female mice and rats.  261 
 
The eTOX database was developed by the European eTOX project, which was a 262 
consortium of 13 pharmaceuticals, data curators, modellers and software developers 263 
funded by the EU Innovative Medicines Initiative (IMI) Joint Undertaking for 7 years 264 
(Steger-Hartmann et al., 2009;Cases et al., 2014;Sanz et al., 2017). The database 265 
provides access to data on repeated dose toxicity and organ specific toxicity studies 266 
and contains models such as like Human outcomes module, Ontobrowser, eTox Lab 267 
and Limtox. It covers data on 1,947 pharmaceuticals out of which 483 labelled as 268 
confidential. COSMOS (Cronin MTD, 2012) was another EU funded project which 269 
aimed to develop in silico models for the prediction of human repeated dose toxicity 270 
of cosmetic ingredients to optimise safety without the use of animals by using 271 
computational models. The tools and approaches includes application of Thresholds 272 
of Toxicological Concern (TTC) of cosmetics related substances. The database includes 273 
14 
 
more than 80,000 chemical records with more than 40,000 unique structures, 12,000 274 
toxicity studies across 27 endpoints for more than 1,600 compounds.  275 
 
II. ADME Databases: 38 ADME databases were identified which captured information on 276 
parameters such as area-under-the-plasma concentration-curve (AUC), maximum 277 
concentration (Cmax), Time to reach maximum concentration (Tmax), half-life (T1/2), 278 
volume of distribution (Vd), clearance (CL) etc13. These data were determined from in 279 
vitro and in vivo ADME studies involving different species (mouse, rats, dogs, 280 
monkeys) as well as humans in clinical studies. Pharmapendium 281 
(https://pharmapendium.com) is one of the most widely used commercial database 282 
(Elsevier group) in the pharmaceutical industry. The database contains information on 283 
4,331 drugs indexed and fully searchable for more than 1.53 million PK data, 295,000 284 
metabolising enzyme and transporters data, 1.57 million safety data, 1.69 million 285 
efficacy data and 115,000 activity data extracted from FDA/ EMA drug approval 286 
documents.  287 
 
A number of databases are particularly useful for the retrieval of information on 288 
metabolites e.g., XmetDB (Spjuth et al., 2016), Metrabase (Mak et al., 2015) and Akos.  289 
XMetDB is an open resource for drugs, xenobiotics and their experimental metabolite 290 
data. It contains 162 observations from 21 scientific papers from 14 journals, covering 291 
117 chemical structures and 95 enzymes. Akos Metabolites (Accelrys) is a restricted 292 
source containing experimental data from in vivo and in vitro studies for about 20,000 293 
parent compounds, 100,000 transformations and 50,000 molecules. It has indexed 294 
relevant metabolic paths for structurally related systems.  295 
 
Other influential databases for PK properties include the ADME database14 which is a 296 
proprietary database from Fujitsu Kyushu Systems (Japan). This provides the latest 297 
and most comprehensive data on interactions of substances with drug metabolising 298 
enzymes and drug transporters that are specific to humans. It contains enzyme kinetic 299 
                                                          
13 References are included in the word supplementary document section III. 
14 
http://www.fujitsu.com/jp/group/kyushu/en/solutions/industry/lifescience/admedatabase/  
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values (Km, Vmax, Ki, Kinactivation, IC50, EC50, T1/2) obtained from the literature. A recent 300 
count shows 35,776 substrates, 28,996 inhibitors, 546 activators as well as 12, 617 301 
data for inducers of CYP450 enzymes. For other enzymes 8,608 substrates, 6,109 302 
inhibitors, 229 activators and 2,220 inducers were included and in the case of 303 
transporters 14,749 substrates, 6,109 inhibitors, 229 activators and 2,220 inducers 304 
were included. The University of Washington’s licensed databases such as Drug-305 
Interaction DB (DIDB), e-PK gene and Organ induced-DDI (OI-DDI) (Hachad et al., 306 
2010;Hachad et al., 2011;Yeung et al., 2015) are also very useful. DIDB has the largest 307 
manually curated collection of in vitro and in vivo data related to drug interactions in 308 
humans. Additionally, it covers pharmacokinetic profiles of drugs, QT (i.e. the time 309 
between the start of the Q wave and the end of the T wave in heart’s electrical cycle) 310 
prolongation data, including results of Thorough QT (TQT) from recent New Drug 311 
Application’s (NDAs) clinical trials data. e-PK gene, is based on pharmacogenomics i.e. 312 
providing in-depth analysis of the impact of genetic variants of enzymes and 313 
transporters on pharmacokinetic responses to drugs and metabolites.  314 
 
OI-DDI contains information on pharmacokinetic drug exposure data for 271 315 
compounds from publicly available renal and hepatic impairment studies presented 316 
together with the maximum change in drug exposure from drug interaction inhibition 317 
studies. Databases on transporters include TP-Search (Ozawa et al., 2004) and UCSF-318 
Trans Portal (Morrissey et al., 2012). TP-Search enables the user to search the 319 
membrane transporters-related information by substrate/inhibitor/inducers 320 
structure or name, gene expression, functions, drug-drug interactions involving 321 
transporters (Km/Ki) etc. It coveres more than 75-membrane transporters across 322 
different tissues in mice, rats and humans.  The University of California, San Francisco’s 323 
UCSF-Trans Portal provides information on transporter expression, substrates, 324 
inhibitors and potential drug-drug interactions. The localisation of transporters in 325 
different organs e.g. blood brain barrier, kidney, liver, placenta, and small intestine is 326 
available with images, notes, references and expression data where available. UCSF 327 
Pharmacogenetics (Kroetz et al., 2009) is a restricted knowledge base providing the 328 
information on genetic variants in membrane transporters in ethnically diverse 329 
populations. The complete list of Solute Carrier Superfamily (SLC) and the ATP Binding 330 
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Cassette (ABC) Superfamily are also provided within UCSF. The user can also access 331 
qPCR expression and MicroArray data.  IDAAPM (Legehar et al., 2016) is a very useful 332 
and freely accessible computational resource for modelling (using KNIME workflows) 333 
to provide information on ADME properties and known adverse effects of FDA 334 
approved drugs taken from FAERS database. It contains information of about 19,226 335 
FDA approval applications for 31,815 products, 2,505 active ingredients, 1,629 336 
molecular structures, 2.5 million adverse effects and 36,963 experimental drug-target 337 
bioactivity data. ADMETlab  is a recent addition in this category which is useful to 338 
predict 31 ADMET endpoints prediction, systematically evaluate PK properties and 339 
druglikeness as well as performing chemical similarity searching using different 340 
fingerprint methods.   341 
 
III. Drug Discovery Databases:  157 databases were identified that relate directly to drug 342 
discovery including: small molecule screening, combinatorial chemistry, molecular 343 
affinity, binding, docking, enzyme interaction, activity, gene expressions, side-effects, 344 
disease, pathways, repurposing of drugs etc15. Some of the pertinent resources on 345 
drug information are DrugBank, DrugCentral, SuperDrug and the FDA’s Orange Book. 346 
DrugBank (Wishart et al., 2008) is one of the most widely used databases that includes 347 
information on drugs targets, enzymes and transporters. The version available at time 348 
of writing contains 11,874 drug entries including 2,474 approved small molecule 349 
drugs, 1,177 approved biotech (protein/peptide) drugs, 129 nutraceuticals and over 350 
5,748 experimental drugs. Additionally, 5,131 drug target/ enzyme/transporter/ 351 
carrier sequences are linked to these drug entries. DrugCentral (Ursu et al., 2017)is 352 
another drug compendium covering 4,531 active ingredients, 3,807 small molecules, 353 
279 biologics, 445 other compounds, 77,484 FDA drug labels, 34,192 prescription only 354 
drug labels, 43,292 OTC drug labels and 97,271 pharmaceutical formulations with FDA 355 
drug labels. The web server for Drug Central also aids in finding the drug gene 356 
signature profile similarity without linking to other resources. SuperDrug (Goede et 357 
al., 2005) contains 4,605 small molecules, 3,993 Biologicals and  612 other drugs, 4,253 358 
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ATC codes, 736,562 3D conformers, 223,860 drug products, 3,006 confirmed biological 359 
targets, 1,450 predicted biological targets and 109,698 side effects.  360 
 
A small number of early drug development resources were also identified; Open 361 
Target (Koscielny et al., 2017) is useful for systematic identification and prioritisation 362 
of targets. At time of writing, it contains 21,149 targets, 2,920,121 associations, and 363 
10,101 diseases. D3R (Gathiaka et al., 2016;Gaieb et al., 2018) is another resource 364 
containing manually curated datasets on validation and improvement of methods in 365 
computer-aided drug design. A single dataset comprises 25 or more congeneric 366 
compounds, 5 – 10 co-crystal structures, related affinity data and a number of known 367 
inactive compounds. Biovia MDDR database was jointly developed by BIOVIA and 368 
Clarivate Analytics. It contains 260,000 biologically relevant compounds and well-369 
defined derivatives. E-LEA3D (Douguet, 2010) is a source for FDA’s registered 370 
molecular structures - 1884 approved between 1939 and 2018 with a molecular 371 
weight ≤ 2000. The 1884 different molecular structures includes structures of 372 
enantiomers and of active metabolites. This resource is dedicated to pharmacology 373 
(molecular structures, PK, Pharmacodynamics (PD) and registration data.  374 
 
Databases useful for exploring binding affinity to targets are also included in Table 3. 375 
BindingDB (Gilson et al., 2016) is an open resource of measured binding affinities, 376 
focusing on the interactions of protein considered to be drug-targets with small, drug 377 
like- molecules and it contains 1,454,892 binding data, for 7,082 protein targets and 378 
652,068 small molecules. AffinDB (Block et al., 2006) is a database of affinity data for 379 
structurally resolved protein-ligand complexes from the Protein Data Bank (PDB) and 380 
it contains 748 affinity data out of which 474 were covered from PDB. Brenda  is a 381 
widely used resource for enzymes information including approximately 3 million data 382 
points from 83,000 enzymes,137,000 literature references and a total of 206,000 383 
enzyme ligands providing functional and structural data.  384 
 
GPCR-LIgand DAtabase (GLIDA) (Okuno et al., 2006)  is a G protein-coupled receptor 385 
(GPCR)-related chemical genomic database that is primarily focused on the correlation 386 
of information between GPCRs and their ligands. It contains 3,738 GPCR-related 387 
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entries (links to Entrez Gene, GPCRDB , UniProt , IUPHAR, KEGG) for 649 ligand entries. 388 
For docking purpose Computed Ligand Binding Energy (CLIBE) (Chen et al., 2002) and 389 
CREDO (Schreyer and Blundell, 2013) are useful. CLIBE is a database developed by 390 
National University of Singapore and useful for the analysis of Drug Binding 391 
Competitiveness. It contains 67,184 entries for ligand binding energy, in which there 392 
are 5,978 distinctive ligands and 2,258 distinctive receptors. In contrast CREDO stores 393 
the interactions between all molecules inside macromolecular complexes from the 394 
Protein Data Bank (PDB). These molecules include proteins, nucleic acids, 395 
carbohydrates as well as small molecules. CREDO has implemented 13, different 396 
interaction types such as hydrogen bonds, halogen bonds, carbonyl interactions and 397 
others. Other resources noted are Target Central Resource Database (TCRD), Pharos 398 
(Nguyen et al., 2017), CARLSBAD (Mathias et al., 2013), GPCR-Ligand Association 399 
Database (GLASS) and GPCR-EXP (Dai et al., 2016).  TCRD and Pharos were both 400 
developed by the Illuminating the Druggable Genome (IDG) program which aimed for 401 
collecting and organising information about the most common protein targets from 402 
four families -GPCRs, kinases, ion channels and nuclear receptors. TCRD collates many 403 
heterogenous gene/protein datasets and Pharos is a multi-modal web interface that 404 
represents the data from TCRD. Overall, the database covers 72 million associations 405 
between all mammalian genes and their attributes collected from 66 open online 406 
major resources. CARLSBAD is an aggregator of many bioactivity databases such as 407 
ChEMBL, IUPHARDb, Psychoactive Drug Screening program (PDSP) Ki, PubChem and 408 
WOMBAT. It provides a single normalised bioactivity value (Ki, EC50 etc.) for chemical-409 
protein target pair. It includes data for 9,32,852 activities, 8,90,323 unique structure-410 
target pairs, 3,739 targets and 1301 diseases. The GLASS database is manually curated 411 
repository for experimentally-validated GPCR-ligand interactions. It contains 3,056 412 
GPCR entries and 335,271 ligand entries. Whereas GPCR-EXP provides information on 413 
experimental and predicted structures of GPCR. It covers data for 55 GPCRs, 282 414 
structures across 9 species (from Protein Data Bank) and 1,076 predicted structures in 415 
human genome. Possum (Ito et al., 2012) is another standalone database for pocket 416 
similarity searching for predicted and experimentally-derived ligand binding sites 417 
covering 5,513,691 known and putative binding sites obtained from Protein Data 418 
Bank.  419 
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Allostery is a process of regulation of biological macromolecule (protein) function 420 
induced by binding of a ligand (small molecule) at an allosteric site (i.e. a distinct site 421 
other than the active site) in an efficient way to control the metabolic mechanisms or 422 
signal-transduction pathways and subsequently increasing the high receptor 423 
selectivity and lowering the target-based toxicity. This concept helped to build the 424 
Allosteric (Shen et al., 2016) database which has compiled 1,788 allosteric target 425 
entries, 77,825 allosteric modulator entries, 82,431 interactions, 1,930 allosteric sites, 426 
56 allosteric pathways, 261 allosteric networks and 3,350 allosteric related diseases.  427 
 
For pain research, there are various database including SuperPain (Gohlke et al., 2014) 428 
and Pain Genes database (PGDB) (LaCroix-Fralish et al., 2007). SuperPain is a database 429 
specifically relating to pain-stimulating and pain-relieving compounds, which bind or 430 
potentially bind or block to ion channels, e.g. those belonging to the family of 431 
Transient Receptor Potential (TRP) channels (TRPV1, TRPM8, TRPA1), human ether-a-432 
go-go related gene (hERG), TREK1, P2X, Acid-sensing ion channels (ASIC) or voltage-433 
gated sodium channels. It contains data on 8,700 ligands (experimentally identified) 434 
and 100,000 putative ligands. PGDB provides analysis of the published pain-related 435 
phenotypes of mutant mice (over 200 different mutants) and covers 430 genes 436 
associated with the pain mechanism.  437 
 
Oncology is another domain where large datasets have been produced and compiled 438 
in databases such as Cancer Target Discovery and Development (CTD2) (Aksoy et al., 439 
2017), CancerResource (Gohlke et al., 2016), canSAR (Tym et al., 2016), CancerDRD 440 
(Kumar et al., 2013), Genomics of Drug Sensitivity in Cancer (GDSC) database (Yang et 441 
al., 2013) etc. CTD2 is very useful platform for translation of high-throughput and high-442 
content genomic and small molecule data for oncology. It contains 10,828 cancer cell-443 
line sensitivity profiling data, 18 oncogenomic screening observations, 156 chemical-444 
genetic interaction mappings, 66 drug-sensitivity screening results, 24 observations 445 
based on reverse phase protein arrays. Whereas CancerResource focuses on cancer 446 
related drug-target interactions, expression and mutation data as well as drug 447 
sensitivity data. It covers data on 48,404 compounds, 3,387 cancer-relevant protein 448 
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targets, 90,744 compound-target interactions, 2,037 cell lines, 19,834 genes, 872,658 449 
mutations, 23,016 genes (expression). CanSAR is another translational platform, 450 
which integrates genomic, protein, pharmacological, drug and chemical data with 451 
structural biology, protein networks and druggability data. CanSAR contains unique 452 
data on 20,316 proteins in human, 556,825 in all species, 143,698 3D structures, 453 
400,892 chains, 12,172 cell lines and 1,962,718 unique structures, 2,148 organisms, 454 
6,367,677 data points from 59,618 studies and 244,099 clinical trials. Whereas 455 
CancerDRD is a database of 148 anticancer drugs and their effectiveness against 456 
around 1000 cancer cell lines. GDSCdb is a partially open resource containing 457 
information on drug sensitivity in cancer cells and molecular markers of drug 458 
response. It contains data on 75,000 experiments testing response to 138 anticancer 459 
drugs across almost 700 cancer cell lines. 460 
  
With the advent of high –throughput in-vitro technologies to systematically 461 
investigate new indications for existing drugs has led to the development of 462 
repurposing databases for personalized medicines such as RepurposeDB (Shameer et 463 
al., 2018), repoDB (Brown and Patel, 2017), The Drug Repurposing Hub (DRH) , 464 
Promiscuous (von Eichborn et al., 2011) etc. RepurposeDB contains information on 465 
253 drugs (74.30%) and protein drugs (25.29%) and 1125 diseases. RepoDB another 466 
repositioning database containing information on 1519 approved drugs, 386 467 
terminated, 199 withdrawn, and 77 suspended drugs. DRH contains data on 10,147 468 
compound samples, 2,247 protein targets, 6,125 unique compounds and 663 drug 469 
indications. Promiscuous connects entities such as drugs, proteins and side effects as 470 
well as mapping the relationships between them using a network visualisation 471 
approach. To date, data are available for 10,208,308 proteins, 25,170 drugs and drug 472 
like compounds and 23,702 drug-target interactions. 473 
 
IV. Drug Information, Clinical Trials and Pharmacovigilance Databases: 116 up-to-date 474 
resources on drug information (medication content, packaging inserts dosing), drug 475 
safety (side-effects), clinical trials information and pharmacovigilance are listed that 476 
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are relevant for patients, researchers, pharmacists or prescribers16. Of these 477 
DailyMed17 is the official provider of Food and Drug Administration (FDA) label 478 
information (package inserts) and has information for 98,961 drug listings as 479 
submitted to the FDA.  Medicines Complete18 is another resource for authoritative 480 
information to support clinical and drug research decisions; it includes publications 481 
such as British National Formulary (BNF), BNF for children, Martindale, Stockley’s Drug 482 
Interactions, Martindale’s Adverse Drug reactions, Drug Administration via Enteral 483 
Feeding Tubes, AHFS Drug Information, Clarke’s Analysis of Drugs and Poisons, Dale 484 
and Appelbe’s Pharmacy and Medicines Law, Dietary Supplements, Drugs in 485 
Pregnancy and Lactation, Handbook on Injectable Drugs, Herbal Medicines, Injectable 486 
Drugs Guide, Kucer’s the use of Antibiotics, Pediatric Injectable Drugs, Pharmaceutical 487 
Excipients, Stockley’s Herbal Medicines Interactions, The Green Guide (rules and 488 
guidance for the pharmaceutical distributors)  and  the Orange Guide (rules and 489 
guidance for the pharmaceutical Manufacturers and distributors). It covers 600,000 490 
plus pages of evidence-based drug information, 200 plus countries access 491 
MedicinesComplete and it has 3.7 million users. MedlinePlus19 is a general public 492 
education related resource, developed by The National Library of Medicine (NLM), a 493 
part of the US National Institutes of Health. It contains information on diseases, 494 
conditions, and wellness issues over 1,000 topics.  495 
 
There are few relevant databases related to pharmacovigilance are listed in this 496 
review such as Side Effect Resource (SIDER) 4.1 (Kuhn et al., 2016), FDA Adverse Event 497 
Reporting System (FAERS) (Fang et al., 2014), Vigibase (Lindquist, 2008) and 498 
EudraVigilance (Postigo et al., 2018). SIDER 4.1 contains information (extracted from 499 
public documents and package inserts) on marketed medicines and their recorded 500 
adverse drug reactions; presently it covers data on 1,430 drugs, 5,868 side effects, 501 
139,756 drug-side effects pairs; 39.9% of drug-side effect pairs have corresponding 502 
frequency of effect information. Another adverse event related database is FAERS 503 
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18 https://about.medicinescomplete.com/ 
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(Fang et al., 2014) which contains adverse event reports, medication error reports and 504 
product quality complaints resulting in adverse events that were submitted to FDA  505 
(from Jan 2004 and presently updated quarterly). It contains 14,160,191 total reports, 506 
8,072,400 serious reports (excluding death) and 1,420,885 death reports. Vigibase 507 
(Lindquist, 2008) is a unique World Health Organisation (WHO) global database of 508 
individual case safety reports (ICSRs), it is linked to medical and drug classifications, 509 
including terminologies such as WHO Adverse Reaction Terminology (ART), Medical 510 
Dictionary for Regulatory Activities (MedDRA), WHO International Statistical 511 
Classification of Diseases (ICD), the medicinal products dictionary and WHODrug. It 512 
holds over 16 million anonymised reports of suspected adverse effects of medicines 513 
suffered by patients. EudraVigilance (Postigo et al., 2018) is the European database of 514 
Suspected Adverse Reaction reports by the European Medical Agency (EMA).  515 
MedDRA  provides a single standardised international medical terminology, which can 516 
be used for regulatory communication and evaluation of data pertaining to medicinal 517 
products for human use. It supports ICH electronic communication within the ICH’s 518 
Electronic Common Technical Document (eCTD) and the E2B Individual Case Safety 519 
Report. There are five levels to the MedDRA hierarchy, at the most specific level it is 520 
“Lowest Level Terms” (LLTs), > 70,000 terms (e.g. feeling queasy), “Preferred Term” 521 
(e.g. nausea), “High Level term” (e.g. nausea and vomiting symptoms), “High level 522 
group term” (GIT signs and symptoms) and “System Organ Class” (e.g. GIT disorders). 523 
ICD-1020 contains guidelines for systematic recording, coding, analysis, interpretation 524 
and comparison of mortality-morbidity data collected in different countries. 525 
ClinicalTrials.gov (Zarin et al., 2011) is a database of privately and publicly funded 526 
clinical studies conducted throughout the world. It is a resource provided by the US 527 
NLM and the user can explore 288,732 research studies in all the 50 states and in 205 528 
countries. Information on clinical studies (summary and protocols) are updated by the 529 
sponsor or principal investigator of the clinical study. The European Clinical Trials 530 
Database21 (EudraCT) is developed and maintained by the European Medicines 531 
Agency. The European Union Clinical Trials Register covers 33,526 clinical trials with a 532 
                                                          
20 https://icd.who.int/browse10/2016/en#/X  
21 https://eudract.ema.europa.eu/  
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EudraCT protocol, of which 5,428 are clinical trials conducted with subjects less than 533 
18 years old. The register also displays information on 18,700 older (12-18 years) 534 
pediatric trials.  535 
 
Ontology driven databases have also emerged recently, as these can help map other 536 
databases, this listing therefore includes resources such as the  Medical Subjects 537 
Headings (MeSH) (Nelson et al., 2001) , National Drug File- Reference Terminology 538 
(NDF-RT) (Pathak and Chute, 2010), Unified Medical Language System (UMLS) 539 
(Humphreys et al., 1998) and The Systematized Nomenclature of Medicine-Clinical 540 
Terms (SNOMED-CT) (Bhattacharyya, 2016). MeSH database provides controlled 541 
vocabulary thesaurus for medical subjects and it includes medical terms (headings, 542 
subheadings, supplementary concept records, publication types) for indexing articles 543 
for PubMed. MeSH contains approx. 26,000 terms and is updated annually.  NDF-RT is 544 
developed by the U.S. Department of Veterans Affairs, Veterans Health 545 
Administration (VHA). It organises drug list into formal representation. The categories 546 
of NDF hierarchical drug classifications are Cellular or Molecular Interactions (MoA), 547 
Chemical Ingredients, Clinical Kinetics (PK), Diseases, Manifestations or Physiologic 548 
States, Dose Forms, Pharmaceutical Preparations, Physiological Effects, Therapeutic 549 
Categories and VA Drug Interactions. NDF-RT is updated monthly as a part of RxNorm. 550 
UMLS is a repository of biomedical vocabularies developed by US NLM. It has three 551 
components- The Metathesaurus® of inter-related medical concepts, Semantic 552 
networks (high-level categories) and the SPECIALIST Lexicon which "contains syntactic, 553 
morphological, and orthographic information for biomedical and common words in 554 
the English language. The UMLS covers 2 milion names for some 900,000 concepts 555 
from > 60 families of biomedical vocabularies, as well as 12 million relations among 556 
these concepts. SNOMED-CT is a database on structured clinical vocabulary for use in 557 
an electronic health record. It provides a standardised way to represent clinical 558 
phrases captured by the clinician and enables automatic interpretation of these. It is 559 
multinational and multilingual, and it contains 340,659 active concepts.  560 
 
V. Biological Databases:  There are 268 biological databases. This category of databases 561 
refers to the resources containing information on enzymes (kinase, GPCRs, CYPs etc.) 562 
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antibodies, receptors, tissue specific gene expressions/ regulations, annotated 563 
protein-peptide sequences, genetic and metabolic signaling, RNA, lipids, immune –564 
system components etc22. Enzyme related information are provided in databases such 565 
as Enzyme Portal (Jassal et al., 2012;Alcántara et al., 2013), GPCRdb (Pándy-Szekeres 566 
et al., 2018), International Union of Basic and Clinical Pharmacology- British 567 
Pharmacological Society (IUPHAR-BPS) Guide to Pharmacology (Hay et al., 2018), 568 
Integrated relational Enzyme database (IntEnz) (Fleischmann et al., 2004), Kinase.com, 569 
Kinweb etc. Enzyme Portal is a comprehensive database by EMBL-EBI and it contains 570 
information on enzymes, such as small-molecule chemistry, biochemical pathways 571 
and drug compounds. It provides a summary of information from UniProt 572 
Knowledgebase, Protein Databank in Europe (PDBe), Rhea (enzyme-catalysed 573 
reactions), Reactome (biochemical pathways), IntEnz (enzyme nomenclature 574 
information), ChEBI and ChEMBL (small molecule chemistry and bioactivity), MACiE 575 
(reaction mechanism) and the Experimental Factor Ontology (EFO). GPCRdb contains 576 
data on GPCR structures and large collections of receptor mutants. The database 577 
covers data on 15,090 proteins, 418 human proteins, 3,547 species, 270 experimental 578 
structures, 184 refined structures, 144,860 ligands, 34,353 mutants and 12,300 ligand 579 
interactions. IUPHAR/BPS Guide to Pharmacology provides data on molecular 580 
interactions between target and ligands from selected papers in pharmacology and 581 
drug discovery since 2003. It covers 2,880 total number of targets, 9,405 ligands and 582 
1,383 approved drugs with clinical use summary.  583 
 
For DNA, RNA and gene datasets, there are number of databases available such as 584 
GenBank (Benson et al., 2013), Gene Expression Ontology (GEO) (Barrett et al., 2013), 585 
The Genotype-Tissue Expression (GTEx) portal (e et al., 2017), Hugo gene 586 
Nomenclature Committee (HGNC) (Gray et al., 2016), Human Protein Atlas (HPA) 587 
(Uhlen et al., 2010), Encyclopedia of DNA element (ENCODE) (The, 2011), Ensembl , 588 
TP-53 (Leroy et al., 2013), European Nucleotide Archive (ENA) (Silvester et al., 2018), 589 
European Genome-phenome Archive (EGA) (Lappalainen et al., 2015) etc. GenBank is 590 
the NIH genetic sequence database, an annotated collection of all publicly available 591 
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DNA sequences. It contains publicly available nucleotide sequences for almost 592 
260,000 formally described species. GEO is a portal for the application ontology for 593 
the domain of gene expression. Its metrics indicates 166,254 classes, 157,102 594 
individuals, 12 properties and 50,996 maximum number of children. GTEx database is 595 
a great resource to study tissue-specific gene expression and regulation. The 11,688 596 
samples were collected from 53 non-diseased tissue sites and 714 donors. HGNC is 597 
the worldwide authority that assigns standardised nomenclature to human genes. It 598 
approves both a short-form abbreviation known as a gene symbol and a longer and 599 
more descriptive name.  HPA database consists of three parts; the Tissue Atlas 600 
provides the distribution of proteins across all major tissues and organs in the human 601 
body, the Cell Atlas provides the subcellular localisation of proteins in single cells and 602 
the Pathology Atlas shows the impact of protein levels for survival of patients with 603 
cancer. In the latest version, the Human Protein Atlas contains more than 26,000 604 
antibodies, targeting proteins from almost 17,000 human genes.  605 
 
The ENCODE consortium is supported by the National Human Genome Research 606 
Institute (NHGRI) and it has systematically mapped regions of transcription, 607 
transcription factor association, chromatin structure and histone modification. The 608 
ENCODE portal contains over 13,000 datasets available through the Portal from 609 
human, mouse, Drosophila and Caenorhabditis elegans assayed under a variety of 610 
different physiological conditions. The Ensembl database provides a bioinformatics 611 
framework to organise biology around the sequences of large genomes. Ensembl 612 
annotate genes, computes multiple alignments, predicts regulatory function and 613 
collects disease data. TP-53 (tumor protein or cellular tumor antigen p53) is a database 614 
related to the structure of the TP53 gene, TP53 isoforms, mutation nomenclature and 615 
the sequence of more than 5,000 tumor samples from 12 cancer types. The current 616 
release contains 80,400 tumors, 6,870 different TP53 variants. The ENA (EMBL-EBI) is 617 
a comprehensive resource on world’s nucleotide sequencing information, raw 618 
sequencing data, sequence assembly information and functional annotation. It 619 
contains information on 2042.8 millions of nucleotide sequences and 5021.7 billions 620 
bases. The EGA contains data on personally identifiable genetic and phenotypic data 621 
resulting from biomedical research projects. In the entire EGA there is a total of 1,706 622 
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studies (960 cancer, 134 cardiovascular, 39 infectious, 59 inflammatory, 63 623 
neurological and 362 others). 624 
 
VI. Protein-Protein Interaction Databases: To understand the relationships between 625 
proteins, protein-protein (PP) interaction studies are required and this has led to the 626 
creation of many valuable databases to catalog and annotate these PP interactions. 627 
54 databases are listed in Table 323. Some of the most valuable resources are Agile 628 
Protein Interactomes Data server (APID) (Alonso-Lopez et al., 2016), The Biological 629 
General Repository for Interaction Datasets (BioGRID) (Chatr-aryamontri et al., 2015), 630 
CancerNet (Meng et al., 2015), CompPPI (Veres et al., 2015), The Database of 631 
Interacting Proteins (DIP) (Xenarios et al., 2000), Database of Macromolecular 632 
Interactions (DOMMINO) (Kuang et al., 2012), gpDB (Theodoropoulou et al., 2008), 633 
GWIDD (Kundrotas et al., 2012), Human Interactome Project (HIP) (Rual et al., 2005), 634 
Innatedb (Breuer et al., 2013), IntAct (Hermjakob et al., 2004) and Manually 635 
Annotated Targets and Drugs Online Resource (MATADOR) (Gunther et al., 2008). 636 
Possibly most relevant is APID which is a collection of protein interactomes for more 637 
than 400 organisms based in the integration of known experimentally validated 638 
protein-protein physical interactions (PPIs). It covers 375,389 interactions and 29,891 639 
interacting proteins. BioGRID contains genetic and protein interactions curated from 640 
the primary biomedical literature for all major model organism species and humans. 641 
It contains 1,607,037 proteins and genetic interactions, 28,093 chemical associations 642 
and 726,378 post translational modifications (PMT) from major model organism 643 
species.  CancerNet is a human cancer-specific miRNA-target interactions, protein-644 
protein interactions (PPIs) and functionally synergistic miRNA pairs database. It 645 
contains interactions across 33 types of human cancers and also PPI information 646 
across 33 main normal tissues and cell types. CompPPI (Veres et al., 2015) stands for 647 
compartmentalised PPI database, which provides qualitative information on the 648 
interactions, proteins and their localizations for PPI network analysis. For human 649 
species, it covers 94,488 proteins, 266,306 localisations and 1,311,184 interactions.  650 
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The DIP database catalogues experimentally determined interactions between 651 
proteins. It combines information from a variety of sources to create a single, 652 
consistent set of protein-protein interactions. It contains 28,826 proteins, covering 653 
834 organisms, 81,762 interactions (lists protein pairs that are known to interact with 654 
each other), results from 81,913 distinct experiments describing an interaction and 655 
8233 data sources. DOMMINO (Kuang et al., 2012) is based on macromolecular 656 
interactions and at time of writing it covers more than 407,000 binary interactions. 657 
The gpDB (Theodoropoulou et al., 2008) is a resource for GPCRs, G-proteins, Effectors 658 
(molecules) and their interactions. It contains 391 entries relating to G-proteins, 2,738 659 
GPCRs entries and 1,390 effectors with data for 469 species. GWIDD (Kundrotas et al., 660 
2012) is an integrated resource for structural studies of protein-protein interactions 661 
on a genome-wide scale covering 126,897 binary interactions, involving 43,976 662 
proteins from 771 different organisms. HIP (Rual et al., 2005) is an open resource on 663 
human protein-protein interactome network and covers 11,999 proteins and 74,820 664 
Interactions. Innatedb (Breuer et al., 2013) is a  knowledge resource for innate 665 
immunity interactions and pathways and covers 27,172 curated interactions and 9460 666 
curated genes. IntAct (Hermjakob et al., 2004) is a common curation platform for 11 667 
molecular interaction databases and containing 572,063 interactions and 107,900 668 
interactors. MATADOR (Gunther et al., 2008) is a unique resource for protein-chemical 669 
interactions and it covers 775 drugs and their interactions with proteins. 670 
 
VII. Omics: This category is related to the resources containing datasets derived from in 671 
vitro highthroughput screening (HTS) studies covering all the datasets in 672 
metabolomics, proteomics, genomics, transcriptomics and fluxomics. This category 673 
contains 60 databases24. A key example  is ArrayExpress (Parkinson et al., 2007) which 674 
is an archive of functional genomics data stores data from high-throughput functional 675 
genomics experiments and covers 71,472 experiments and 2,311,652 bio assays. It 676 
accepts all functional genomics data generated from micoarray or next-generation 677 
sequencing (NGS) platforms. The Biochemical Genetic and Genomic (BiGG) database 678 
(King et al., 2016) is a  resource based on more than 70 genome-scale metabolic 679 
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networks. Genes in the BiGG models are mapped to NCBI genome annotations, and 680 
metabolites are linked to many external databases (KEGG, PubChem, and many more). 681 
BioSample (Barrett et al., 2012) contains descriptive information about almost 2 682 
million records (a cell line, a tissue biopsy etc.) encompassing 18,000 species whereas 683 
Biostudies  is a repository for descriptions of biological studies from large projects (e.g. 684 
Blueprint, Europe PubMed Central, Eurocan Platform and diXa data warehouse) and 685 
individuals. Currently it covers 2,552,610 files, 2,824,924 links, 4 projects and 686 
1,214,179 studies. Cancer GenomicHub  is a repository that enables data sharing 687 
across cancer genomic studies in support of precision medicine. This database is 688 
derived from 40 projects, 61 primary sites, 32,555 cases, 356,381 files, 22,147 genes, 689 
and 3,142,246 mutations datasets. The chronic kidney disease database (CKDdb) 690 
(Singh et al., 2012) contains multi-omic studies (microRNA, genomics, peptidomics, 691 
proteomics and metabolomics) of chronic kidney disease (CKD), disease-related and 692 
diseases leading to this trait. Presently it has differential expression data from 49,395 693 
molecule entries (redundant), of which 16,885 are unique molecules (non-redundant) 694 
from 377 manually curated studies of 230 publications. Disnor (Lo Surdo et al., 2018), 695 
DrugSig (Wu et al., 2017), DisGeNet (Piñero et al., 2017), Drug Gene Interaction 696 
Database (DGIdb) (Griffith et al., 2013), Online Mendelian Inheritance in Man (OMIM) 697 
(Hamosh et al., 2005) are important resources for exploring the genes and disease 698 
domain. Disnor contains information on more than 3,700 disease-pathways and 699 
linking approximately 2,600 disease genes to diseases. Whereas DrugSig contains 700 
information on drug induced gene signature for drug repositioning for more than 1300 701 
drugs. DisGeNet contains 561,119 gene-disease associations (GDAs), between 17,074 702 
genes and 20,370 diseases, disorders, traits, and clinical or abnormal human 703 
phenotypes. DGIdb contains over 40,000 genes and 10,000 drugs involved in over 704 
15,000 drug-gene interactions or belonging to one of 39 potentially druggable gene 705 
categories whereas OMIM is a widely used, an Online Catalog of Human Genes and 706 
Genetic Disorders and traits. Omics Discovery Index (Omics DI) (Perez-Riverol et al., 707 
2017) is a great resource containing heterogeneous omics data covering 452,800 708 
datasets, 65,200 species, 308,300 genomics, 1,600 tissues, 124,400 transcriptomics, 709 
19 repositories and 7,300 multiomics datasets. The Human Metabolome Database 710 
(HMDB) (Wishart et al., 2017) is a widely used database on small molecule metabolites 711 
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found in the human body covering 114,110 metabolites entries (both water and lipid 712 
soluble) and linked to 5,702 protein sequences. Another useful resource on 713 
metabolites is the Metabolomics workbench (Sud et al., 2016), it contains structures 714 
and annotations of  biologically relevant metabolites (> 61,000 entries). MetaMapTox 715 
(Fabian et al., 2016) is a licensed resource for metabolite profiles from rat plasma and 716 
comprehensive pharmacological and toxicological data. Overall, it covers 25 specific 717 
and predictive toxicological mode of action (MoA) in eleven different target organs. 718 
RefSeq (Nasko et al., 2018) is a comprehensive, integrated, non-redundant, well-719 
annotated set of sequences, including genomic DNA, 20,905,608 transcripts, and 720 
100,043,962 proteins and 73,996 organisms. MetaboLights (Kale et al., 2016) contains 721 
cross-species, cross-technique and covers metabolite structures and their reference 722 
spectra as well as their biological roles, locations and concentrations, and 723 
experimental data from metabolic experiments. PharmacoDB (Smirnov et al., 2018) is 724 
a  cancer pharmacogenomic database covering 7 datasets, 41 tissues, 1,691 cell lines, 725 
19,933 genes, 759 drugs and 650,894 experiments. TCGA (Weinstein et al., 2013) is 726 
another resource on cancer genome data containing an array of molecular alterations 727 
underlying 206 cases of adult soft tissue sarcomas. RGED (Zhang et al., 2014) is a 728 
database of gene expression profiles in kidney disease which covers 55 RNA-sequence 729 
data, 5,299 DNA microarray, 101 cell lines and 5,253 tissues. Connectivity Map (Lamb 730 
et al., 2006) is a very large genome-scale library of cellular signatures that catalogues 731 
transcriptional responses to chemical, genetic, and disease perturbation. It contains 732 
more than 1 million profiles resulting from perturbations of multiple cell types.  733 
VIII. Pathways-based databases: Pathways based toxicity databases are useful in the 734 
development of AOPs. This category contains 38 databases25. Important pathway 735 
based databases includes AOP-wiki or Wiki Pathways, Effectopedia (Vinken et al., 736 
2017), KEGG (Kanehisa and Goto, 2000), Pathway commons (Cerami et al., 2011), 737 
Reactome (Croft et al., 2011), PathCards (Belinky et al., 2015), XTalkDB (Sam et al., 738 
2017) etc. Effectopedia is a part of AOP knowledge base, which has four platforms–739 
AOP-Wiki, Effectopedia, AOP Xplorer and Intermediate Effects DB. It contains 244 740 
AOPs and 1806 key events. KEGG is a vast encyclopedia of genes and genomes and 741 
                                                          
25 References are included in the word supplementary document section IX. 
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classified into many modules as Pathway, Brite, Module, Orthology, Genome, Genes, 742 
Compound, Glycan, Reaction, Enzyme, Disease, Drug etc. Pathway Commons is a 743 
collection of publicly available pathway data from multiple organisms covering 4000 744 
pathways and 1.3M interactions. Reactome is a unique database, which includes 745 
transformations of entities such as transport from one compartment to another and 746 
interaction to form a complex, as well as the chemical transformations of classical 747 
biochemistry. Its latest version includes 2244 human pathways, 12,047 reactions, 748 
10,778 proteins and 1948 small molecules. PathCards is an integrated database of 749 
human biological pathways and their annotations. In addition, the human pathways 750 
are clustered into SuperPaths based on gene content similarity. The other DBs such as 751 
Genecards (Safran et al., 2010), MalaCards (Rappaport et al., 2014) and GeneLoc 752 
(Rosen et al., 2003) could be useful along with PathCard database. Overall, it contains 753 
1289 SuperPath entries, consolidated from 12 sources. XTalkDB is based on scientific 754 
literature supporting crosstalk between pairs of signaling pathways and presently 755 
contains 650 curated pathway pairs, 345 crosstalking pathway pairs, 1697-curated 756 
publications. 757 
 
IX. Patent Databases: 9 databases were identified relating to patents26; these are of 758 
paramount importance in drug discovery, drug formulations, production and 759 
marketing of new molecules (Heifets and Jurisica, 2012;Papadatos et al., 2016). In 760 
addition, databases which contained information on chemical structure, synthesis, in 761 
vitro or in vivo mode of actions etc. are included. Derwent Discovery27 covers patents 762 
from 32 countries and contains 141.3 million backward citations (cited), 148.9 million 763 
forward citations (citing), 34.5 million literature citations. Whereas the European 764 
Patent Office (EPO)28 provides free access to over 100 million patent documents. 765 
SureChEMBL (Papadatos et al., 2016) contains compounds chemistry extracted from 766 
the full text, images and attachments of patent documents from major patent 767 
                                                          
26 References are included in the word supplementary document section X.  
27 https://clarivate.com/products/derwent-world-patents-index/ 
28 https://www.epo.org/index.html  
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authorities (WIPO, USPTO and EPO). It contains 17 million compounds extracted from 768 
14 million patent documents. 769 
 
X. Environmental Databases: There are 30 databases with information on the effects of 770 
chemcials to the environment and non-human species29. This category of databases 771 
are related to potential, hazardous, or toxic chemicals, which are ubiquitous in nature 772 
and are present in air, water, food, soil, dust consumer goods and are detected in the 773 
human body. The Agency for Toxic Substances and Disease Registry (ATSDR) DB 774 
(Johnson, 1995) is maintained by the U.S. Department of Health and Health Services, 775 
useful in protecting the communities from harmful health effects related to exposure 776 
to natural and man-made hazardous substances. It contains A-Z chemical lists of 275 777 
substances and their toxicological profiles. The Hazardous Substances Data Bank 778 
(HSDB) (Fonger, 1995) is another toxicology databank  from TOXNET and it covers 779 
5,800 records on human exposure, industrial hygiene, emergency handling 780 
procedures, environmental fate, regulatory requirements etc. CEDI30 and ADI DB  are 781 
related to Cumulative Estimated Daily Intakes (CEDIs) and Acceptable Daily Intakes 782 
(ADIs) for a large number of food contact substances. The database contains 783 
information on over 3000 substances. 784 
The U.S. EPA’s ECOTOX database31 provides information on adverse effects of single 785 
chemical stressors to ecologically relevant aquatic and terrestrial species. It contains 786 
data relating to 11,655 chemicals, 12,630 species obtained from 48,064 references 787 
and 919,123 individual results. The Integrated Risk Information System (IRIS) is 788 
another product from U.S. EPA and it contains basic information about the risk 789 
assessment for groups of chemicals or complex mixtures. It provides toxicity values 790 
for health effects resulting from chronic exposure to more than 500 chemicals: 791 
Reference Concentration (RfC), Reference Dose (RfD), Cancer descriptors, Oral slope 792 
factor (the slope factor used with administered doses to estimate the probability of 793 
increased cancer incidence over a lifetime) etc.  794 
                                                          
29 References are included in the word supplementary document section XI. 
30 https://www.fda.gov/Food/IngredientsPackagingLabeling/PackagingFCS/CEDI/default.htm 
31 https://cfpub.epa.gov/ecotox/ 
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The European Centre for Ecotoxicology and Toxicology of Chemicals- Human Exposure 795 
Assessment Tools Database (ECETOC-heatDB) is a public directory of exposure data 796 
sources as well as available tools for exposure. Haz-Map® is a relational database of 797 
hazardous chemicals and occupational diseases. The database currently contains 798 
12,086 chemical and biological agents, 240 diseases, 121 findings (signs and 799 
symptoms), hazard specific to 261 jobs, 243 job tasks, 54 industrial processes, 624 800 
industries, and 27 non-occupational activities. LINCS (Liu et al., 2015) is a standalone 801 
library of molecular signatures describing how different types of cells respond to a 802 
variety of chemicals called “perbutagens”. At time of writing, this comprised 391 803 
datasets covering 41,847 small molecules, 1,127 cell types derived from different 804 
organs, 978 genes, 1469 proteins/155 peptide probes and 8 antibodies. Another 805 
noteworthy resource is the OECD QSAR Toolbox, a tool for grouping of chemicals for 806 
read-across that can be applied to data gap filling.  It contains 69 profilers (e.g. DNA 807 
binding, protein binding, acute aquatic toxicity, carcinogenicity alerts, in vitro and in 808 
vivo mutagenicity alerts, keratinocyte gene expression, HESS profiler etc.) and 55 809 
databases (CPDB, DART, Ecotox, RepDose, ToxcastDB, ZEBET, developmental toxicity 810 
database (CAESAR), EFSA Food Tox Hazard Database, EFSA Genotoxicity, REACH 811 
bioaccumulation data, GARDskin database etc.)  with over 70,000 chemicals and 812 
2,116,700 data points.   813 
 
XI. Animal Alternative Databases: 39 Animal alternative databases were identified 814 
relating to data resources32, which assist researchers in complying with the 3Rs 815 
philosophy of reduction, refinement and replacement of animal use by . Examples of 816 
these databases include: Bibliography on Alternatives to Animal Testing (ALTBIB) 817 
(Liebsch et al., 2011) that provides citations from year 2000 to present year. AnimAlt-818 
ZEBET (Grune et al., 2000) is another unique resource, which includes high quality, 819 
scientifically recognised 149 alternative methods to standard animal tests in the field 820 
of toxicology and pharmacology as well as fundamental research. Bgee  provides 821 
information on gene expression patterns in 29 animal species, produced from multiple 822 
data types such as RNA-Seq, Affymetrix etc. The EURL ECVAM Database service on 823 
                                                          
32 References are included in the word supplementary document section XII. 
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Alternative Methods to animal experimentation (DB-ALM)33 developed by the EU Joint 824 
Research Centre (JRC)  provides evaluated information on development and 825 
applications of advanced and alternative methods to animal experimentation in 826 
biomedical sciences and toxicology, both in research and for regulatory purposes. The 827 
Tracking System for Alternative Methods towards Regulatory Acceptance (TSAR) 828 
database34 is useful in identifying alternative non-animal methods that have been 829 
proposed for regulatory safety or efficacy testing of chemicals or biological agents 830 
such as vaccines. For in vitro related DBs, Cellosaurus35  - a knowledge resource on cell 831 
lines is a good example  covering 109,135 cell lines (81,617 human, 19,451 mouse, 832 
1,952 rat).  833 
 
The Fetal Calf Serum Free database (FCS-Free Db)36 provides a list of FCS-free media 834 
available for specific cell lines or cell types. The International Cell Line Authentication 835 
Committee (ICLAC)37 provides lists of 4,000 cell lines that are currently known to be 836 
cross-contaminated or otherwise misidentified or arising from the work of 837 
laboratories and cell line repositories worldwide. LifeMap Discovery®, Cells and 838 
Tissues Database (Edgar et al., 2013) covers data in embryonic development, stem cell 839 
differentiation, regenerative medicine and in vivo and in vitro gene expression data 840 
curated from scientific literature and HTS data sources.  Non-neoplastic Lesion ATLAS 841 
(Schmidt, 2014;W Schmidt, 2014) is a very useful guide for standardising terminology 842 
in toxicological pathology for rodents. Another useful database is Organ System 843 
Heterogeneity DB, which provides information on the phenotypic heterogeneity of 844 
diseases, drugs and mutations in mouse genes on 26 different organ systems defined 845 
in using MedDRA ontology at the SOC (System Organ Class) level. The Interspecies 846 
database which helps to select the most appropriate animal model, which is essential 847 
for efficient extrapolation of animal data to humans or other animals. It provides 848 
information on physiological, anatomical and biochemical parameters across species.  849 
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36 https://fcs-free.org/ 
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XII. Nanomaterial Toxicity Databases: 22 databases exist that contain information on the 850 
properties and toxicity of nanomaterials or their products38. The databases include 851 
NANoREG - eNanoMapper database (Jeliazkova et al., 2015), developed by EU FP7 852 
eNanoMapper project and it contains toxicological data for the nanomaterials 853 
collected by 85 partners across the world. NHECD (Maimon and Browarnik, 2010) is  854 
another free database with its main objectives to study the impact of nanoparticles 855 
on health, safety and environment. It has curated a large and developing collection of 856 
published data on environmental and health effects following exposure to 857 
nanomaterials. The EU Nano Safety Cluster is an open platform containing the Horizon 858 
2020 projects (e.g. SmartNanoTox, NanoReg II, PATROLS etc.) addressing the safety of 859 
materials and technologies enabled by the use of nanoparticles. The Nano- Database39 860 
is developed by the DTU Environment, the Danish Ecological Council and Danish 861 
Consumer Council. It consists of assessments of the nanomaterials used in various 862 
consumer products and NanoRisk Cat categorization. There are nearly 3,036 products 863 
in this database. The Nano database40 created by Nature and Springer. The database 864 
contains data on nanomaterials, methods of production, and nano-instruments. The 865 
data have been curated from articles, patents, and other scientific sources. StatNano41 866 
is another comprehensive database on 7,000 nanotechnology products. It also 867 
contains analytical reports on the trend of nanotechnology influence on different 868 
industries, nanostructures and nano materials. 869 
 
4.0  Discussion  870 
With the advances in HTS, chemical synthesis and biological screening (activity, potency, 871 
safety profiles), the number of commercially or publicly available databases containing this 872 
information has expanded rapidly. This review has resulted in the compilation of nearly 1,000 873 
databases which have been systematically grouped and classified based on content and 874 
potential applications. The databases listed cover many areas including: chemical 875 
                                                          
38 References are included in the word supplementary document section XIII. 
39 http://nanodb.dk/en/ 
40 https://nano.nature.com/  
41 https://statnano.com/ 
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information, drug screening, toxicity (including toxicity of nanomaterials), ADME, binding, 876 
docking, clinical trials, pharmacovigilance, genes, enzymes, interactions, omics, pathways, 877 
patent information, environmental exposure and databases providing information on  878 
alternatives to animals.  879 
Criteria for characterising databases were considered as summarised in Table 2. The essential 880 
criteria were accessibility, relevance of endpoints, chemical identifiers, acceptable ontology, 881 
appropriate (or readily convertible) units, ease of data download in different formats and 882 
interoperability. Desirable criteria includes access to metadata (study proptocols and 883 
statistics), an assessment of the data quality, ease of use, relevant data description (e.g 884 
classification codes) and currency of data. Ontology based databases were also listed which 885 
are useful to integrate the semantic data. For efficient database integration, flexible and 886 
robust APIs are essential to support large datasets. One of the significant bottlenecks in 887 
database integration is identifying  unique data types to ascertain the overlap between data 888 
in two or more databases. 889 
Several factors need to be considered when using the increasing number of data resources 890 
for predictive toxicology and other purposes. A very important aspect is the accuracy and 891 
uniformity of the identity of the chemical and its chemical structure. Uniform chemical 892 
structures are often not included in databases and, on occasions, may even be incorrect. 893 
Further complications may arise as different salt forms, enantiomers, or isotopes may not be 894 
differentiated. One means to assist in the confirmation of the the identity of chemicals is to 895 
include a machine–readable representation of the chemical structure (e.g. SMILES, InChI, 896 
SDF), along with the key identifiers, such as InChIkeys. Linked to the need for correct chemical 897 
identifiers is the prerequisite for high quality chemical structures to ensure the accuracy, 898 
completeness and consistency of the information stored in databases. The process of 899 
checking the accuracy, or otherwise, of chemical structures can be undertaken using the 900 
InChIs and SMILES representations (amongst others). This helps to avoid incorrect structures 901 
by detecting duplicate chemical structures, mismatches between structures, different 902 
stereoisomer/ tautomer forms, mesomeric effects, hypervalency (atom centre displays 903 
valency outside its normal value) and numerous other issues relating to chemical bonds and 904 
inorganic elements (Fourches et al., 2010). To standardise and normalise the databases, 905 
methods such as chemical structure standardisation (removal of mixtures, inorganics, 906 
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organometallics, salts, solvents and fragments; normalisation of specific 907 
chemotypes/metabolites; treatment of tautomeric forms; removal of duplicates), assigning 908 
the unique IDs for the samples, de-duplication of the experimental datasets, validation of 909 
omic technologies (Sauer et al., 2017) and avoiding multiple measurements for the same 910 
parameters etc. should be applied. One critical step in the standardisation or normalisation 911 
procedure is to compile datasets with uniform unit values for a particular parameter derived 912 
from heterogonous resources. Uniform units are required to compare and analyse multiple 913 
datasets. For example,  whilst many data exist for pharmacokinetics properties, there is no or 914 
little consistency even in the key parameters, often with discrepancies or differences in 915 
units/measured values. However, taking an essential propery such as intrinsic clearance 916 
(Clint) measured in vitro for enzymes as an example, the variability in units can be corrected 917 
and normalised to mL/min/g of protein.   918 
To check the accuracy, completeness and consistency of the databases, a number of 919 
qualitative and quantitative methods can be used. For accuracy, the quality of the data in the 920 
databases, i.e. chemical structures, can be confirmed against CAS numbers by cross-921 
referencing with chemical name. The records for the data generated should be mentioned on 922 
the website as well as details and results of the validation along with the statistics (number 923 
of compounds covered, version number). Consistency can be checked for the data in different 924 
version updates of the database, however, this information is seldom provided. Metadata i.e. 925 
a representation of supporting data in different formats, are not systematically implemented 926 
in databases. Resolving this issue would assist in mapping datasets to each other and save 927 
time in finding a relevant study. It is also clear that many data resources contain many of the 928 
same data and sources of information. In addition, many of the data published in journals, 929 
books or dataset compilations have been merged  in single platforms (e.g. PubChem) which 930 
makes searching easier. As such, this has resulted in a great deal of overlap between existing 931 
databases and potentially the propagation of errors (i.e. an error being carried forward across 932 
data sources due to a lack of manual checking). However, overlap between the databases is 933 
not considered a major problem and it could be minimised by clearly identifying the origin of 934 
data and using primary sources where possible. Ontologies help in mapping and data 935 
integration by providing the syntax for describing classes (or concepts), properties and 936 
relationships between classes in the domain of discourse. Mapping between the schema 937 
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(organisation of data as a blueprint of how the database is constructed) and domain 938 
ontologies are an important component for information integration. Whereas, metadata are 939 
data that describe the elements in a dataset (e.g. Name of the table, Type of columns and 940 
relationships between them) and help in importing the dataset files from one resource to 941 
another or consolidate multiple databases into a single database. For many databases 942 
licensing terms and conditions are provided. Clear license information is crucial so that the 943 
end user knows what can be done with the metadata. Open licenses for databases encourage 944 
access and download of data in a machine-readable format together with their metadata. 945 
Some databases apply the license to the whole database or some third party datasests. The 946 
end users are recommended to read and understand the licensing information correctly to 947 
know whether the contents are provided for commercial or educational research purposes 948 
only. The researchers or data owners are also recommended to publish the metadata under 949 
a public domain license to ensure wide distribution and reuse. Interoperable databases, i.e. 950 
those with a user-friendly, interface, and  the capacity for easy interaction and exchange with 951 
the other systems, are favoured. The choice of a particular API depends on the size of the 952 
database and the programming skills of the developer. Creating databases with greater 953 
interoperability will increase their utility and potential application in diverse areas. In 954 
addition, database mapping can be defined as the process of identifying key data sources 955 
(web pages, flat files, XML-formatted data, directly accessible DBs) by using methods such as 956 
ontologies, programming codes, graphical interfaces and then linking those relevant 957 
databases before merging (integration) into a common platform or a single database. 958 
Mapping of different databases depends on the technical content and architecture of the 959 
datasets. For better mapping and integration easy access to the metadata are preferred. The 960 
content accessibility provided by the different databases vary: the majority of databases are 961 
open platform enabling searching of scientific data, some facilitate data downloading in 962 
different formats. Access to some databases is restricted e.g. commercially available 963 
databases.   964 
Looking to the future and potential use of in silico resources, the integration of databases with 965 
in silico tools for predicting the properties or activities of compounds could be useful for early 966 
decision making in drug discovery and chemical risk assessment. The computational tools 967 
should not be limited to only chemistry or biology but should be able to link chemistry with 968 
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activity, toxicity and the underlying mechanistic information. In other words, the tools should 969 
integrate information on dosimetry, human exposure (in silico) and in vitro toxicity screening 970 
data to provide a better chemical safety risk assessment. 971 
An enormous variety of databases relating to in silico toxicology, prediction and safety 972 
assessment are available; other potential uses of these databases include the identification 973 
of chemically and/or biologically similar chemicals for read across purposes. In future 974 
development of databases key attributes to consider include data quality, accessibility, ease 975 
of downloading the data, chemical space coverage and range of bioactiviy.  976 
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Table 1: Previous review articles for identification of databases relevant to chemistry and toxicology  
Reference Categories covered No. of Dbs covered Remarks 
Alexander-Dann et al., 2018 Gene expression  12 Microarray software, database management systems  
Ayvaz et al., 2015 Potential DDI information resources 14 Clinical, natural language corpora, pharmacovigilance data 
sources 
Benigni et al., 2013 Chemical mutagenicity and carcinogenecity 18 QSAR, Cluster of toxicity databases, risk assessment 
Bianco et al., 2013  Genetic disease research databases 18 Sample sequence, gene expression and post-transcriptional 
regulation 
Bower et al., 2017 Toxicity databases  Toxicity data resources and format (ToxML) discussed 
Cha et al., 2018 Drug repurposing databases 29 Drugs and disease (omics, genomics, transcriptomics, 
proteomics, epigenetic) databases, omics tools also available 
Chen et al., 2016 Drug-target interaction databases 15 Webserver databases and computational models included 
Cheng et al., 2017 Drug Target interaction databases 28 3D structure, binding affinities Db, screening programs and 
data repositories, Curated drug-target interactions 
Cronin, 2005 Toxicology databases 26 Sources of chemical structures also described 
Cronin, 2010 Toxicology databases 33 QSAR modelling purpose 
Ekins and Williams, 2010 ADME/Tox databases 13 Targeted data types required for ADME/Tox and PK databases 
Ekins et al., 2005 Systems biology and ADMET  33 HT techniques, systems biology modelling and ADMET 
modelling included 
Ekins et al., 2011 Tuberculosis (TB)  databases 13 Computational databases, pathways, cheminformatics tools for 
TB  
Fostel et al., 2014 Toxicogenomics 14 Relevant Databases and Consortia Supporting Systems 
Toxicology Research 
Fouretier  et al., 2016 Pharmacovigilance (PV)  11 North American PV databases not covered 
Fotis et al., 2018 Omic repositories 48 Omics and pathways, tools provided 
González-Medina et al., 2017 Chemical biology databases 11 Online servers and tools for mining chemical and target spaces   
Hersey et al., 2015 Chemical databases 10 Bioactivity, Patents, drugs and target, available compound and 
other 
Ji et al., 2003b Proteins associated with drug therapeutic effects, 
ADR and ADME  
44 Targets related databases and their websites 
Jonsdottir et al., 2005 Prediction methods, cheminformatics DBs 23 General, screening compounds, medicinal agents, 
physicochemical and ADMET properties  
Judson, 2010 Toxicology databases 15 In vitro, in vivo toxicity and ontology-based databases 
Kiyosawa et al., 2006 Microarray databases 7 Large scale toxicogenomics databases 
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Koutsoukas et al., 2011 Bioactivity and target predictions 20 Bioactivity and target-based databases, WS for target 
prediction of small molecules 
Katsila et al., 2016 Drug target identification databases 19 Human metabolome, pathway analysis, chemogenomic data, 
drug-target, protein, disease specific target DB, 
pharmacogenomic, toxicogenomic, target-toxin, protein 
expression, therapeutic target  
Loging et al., 2011 Drug repurposing  11 Public resources  
Luo et al., 2017 DILI databases 11 Liver specific injury and broader drug databases 
Madden, 2013  Toxicity, reactivity, chemical property and structural 
data 
30 Assessment of quality data provided  (Klimisch score criteria) 
Madden et al., 2019 PBPK & ADME Resources  ~100 Resources to predict external exposure, physico-chemical 
properties, ADME properties, physiological/anatomical 
parameters and model structures for specific organs, PBPK 
modelling softwares, similar chemicals  
Nicola et al., 2012 Medicinal chemistry databases 12 Databases of binding and bioactivity data for small molecules 
Opassi et al., 2018 Chemical-Biology databases 28 Virtually accessible chemical spaces, biology databases 
Oprea and Tropsha, 2006 Target, chemical and bioactivity 24 Integration of the databases  
Papadopoulos et al., 2016 Omics databases on kidney disease 18 General omics and kidney specific databases 
Peach et al., 2012 Metabolism related content  11 Software for metabolism predictions  
Polen et al., 2008 Online drug databases 14 Drug databases for infectious disease therapies 
Rana et al., 2012 Receptor and binding databases 26  Websites for computational, GPCR specific and nuclear 
receptors 
Rigden et al., 2016 Molecular biology databases  157 Nucleic acids, genetic basis of cancer, patented drugs, their 
side effects, withdrawn drugs, and potential drug targets 
Sato et al., 2018 hERG inhibitors, cardiotoxicity  4 hERG inhibition by small molecules 
Sim et al., 2011 Pharmacogenetics 7 Pharmacogenomics, CYP, NAT, Transporters, UGT, ADME Dbs  
Smalter Hall et al., 2013 Chemical and biological databases 20 Protein interaction, pathways, drug discovery, mathematical 
models databases, data formats for proteomics and genomics 
and cheminformatics provided. 
Torporov et al., 2014 Drug toxicity databases 27 Software for QSAR analysis of toxic endpoints also given 
Williams, 2008 Chemical property databases 15 Publicly available databases 
Wishart, 2014 Drug metabolism research 13 Online databases and prediction software for drug metabolism  
Wooden et al., 2017 Big data analysis resources 18 Big data for gastro intestinal and liver diseases 
Young, 2002 Genetic toxicology web resources 13 EPA, FDA, US NLM toxicity databases discussed 
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Zou et al., 2015 Biological databases for human research > 100 DNA, RNA, Proteins, expressions, pathways, disease, ontology 
and literature-based databases listed 
Zhang et al., 2015 Pharmacogenomics 8 Web resources 
987 
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     Table 2: Considerations for characterising the databases  
Essentials  
Accessibility (open access; registration; license required)  
Interoperability (linkage via API or importable)  
Acceptable ontology and units (or readily converted) 
Appropriate identifiers used (e.g. InChI)  
 Relevance of endpoint (s) project: physico-chemical properties; ADME (including metabolite data); pharmacological activity; toxicity; clinical trial data; adverse events 
reports 
Desirables 
Access to metadata 
Information provided on study protocols/statistics 
Data quality assessment and accuracy of information 
Ease of use/navigation 
Appropriate classification codes (e.g. therapeutic group classification) 
Currency of information (historical; frequency of updates); size of resource (amount of data / level of detail) 
Nature of information / potential use 
Type of data recorded (in vitro / in vivo / biomarker / omics / targets) etc. 
Relevance to overall aim of any project (e.g. extrapolation from preclinical to clinical) 
Experimental versus predicted values 
Insights into mechanisms of action / elicitation of molecular initiating event 
Suitability for modelling, read-across or similarity searching 
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Table 3: Complete listing of all databases (with the URL links) identified in this study grouped according to content 
                                  Chemistry (80)   Toxicological  (57)   ADME (38) 
AuroraFineChem DOCK Blaster OCHEM ACToR Lhasa Carcinogenecity Db ADME-AP 
Biovia ACD  Danish QSAR Db OSDDChem Acute Tox LIVERTOX ADME Db 
Biovia SCD  Elsevier Reaxys Organic syntheses Akos Toxicity LTKB ADMET SAR 
BioByte  eChemPortal PubChem Biovia Toxicity MDL-Toxicity / met ADMET Lab 
CAS SciFinder e-Drug3D PPD CPDB     NCI-60 (DTP) ADMENET 
CCID  eMolecules PCDDB COSMOS NCTRIcdb Akos Metabolites 
Cfam  eQuilibrator Probes & drugs portal CTD Open TG-GATEs AMED Cardiotoxicity 
ChemDB FDB-17 Probe Miner CEBS OEHHA Chemical Bioprint 
CCDS FilTer BaSe R & D Chemicals ChemTunes  pCEC BBB 
Chemistry Dashboard FDA UNII SDBS Coptis Tox PROTOX CYP DI table 
ChEMBL GDB Db Spresi CCRIS PAFA CYP P450 Inhibitors 
ChemAgora GOSTAR MedChem Sigma-Aldrich CREST Db RTECS DIDB 
ChemSpider HDAC Inhibitors Base Symmetry @Otterbein DSSTox Repdose EDETOX Db 
Chemfinder  IUPAC-NIST Solubility SPIM diXa Super Toxic e-PK gene 
ChEBI  IUCLID SIDS DevTox SAR Genetox Db ECVAM KinParDB 
Common chemistry  JRC QSAR Model Db Wikipedia Drug Matrix SAR Carcinogenicity FINDbase 
Chemspace LipidBank WebReactions DART Toxline HIA 
Chembiobase Lipidomics Gateway ZINC15 eTox ToxDB IDAAPM 
Chemexper  LookChem  EADB Toxygates IIMDB 
CCCBDB Massbank   EDKB Toxbank Liceptor 
ChEBI MolPort  ETOXNET Tox 21 Microsomal Stability 
CERES METLIN   EASIS Toxcast METRABASE 
Chem synthesis mzCloud   EDCs DataBank ToxRefDB OI-DDI 
COD MERCK INDEX Online  ECVAM Geno   T3DB pKa DB 
CheLIST MMsINC  FeDTex TerraTox PACT-F 
ChemIDplus NCI-OPEN Db  Gene-Tox Vitic Nexus PK/DB 
Chemistry Guide NICEATM Ref Chem Lists  HESS   Pharmapendium 
ChemACX NMRShiftDB  ISSTOX  PDSP Ki 
ChemSink NIST Chemical Kinetics  ITER  Tox-database.net 
ChemSub Online NIST Chemistry Web Book  JECDB  TransportDB 
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Common Compound Library NIST, Atomic Spectra  Leadscope  TCDB 
     TR MetaDrug 
ADME….                                          Drug  Discovery  (157)  Clinical trials/ PV (116)      
TP-Search Allosteric database Cyclonet Ensembl Protists Metabase PoSSuM ATC-DDD 
TTD ASDCD CPRG ExCAPE-DB Metacore PathogenBox AACT DB 
TRANSFORMER AffinDB ChEMBL-NTD e-Drug3D MOSAIC RepurposeDB ALFRED 
UCSF ph’genetics APD  CancerDRD EMBASE MEDock Rx Nav AFND 
UCSF-FDA TransPortal AutoBind  Cell Image Library ELDD MICAD Sc-PDB   AutDB 
WOMBAT-PK ARDB CCGD FDA NDC MTB SuperDRUG 2.0 BfArM (UAW-
Datenbank) 
XMetDb Abiofilm Chemical Probes FDA Orange Book mSignatureDB Super Target BmDR   
 
Autism Chromosome 
Rearrangement 
CARD FaCD Online mutLBSgeneDB SM2miR 
Bioportal 
 ADHDgene cBioPortal Flow Repository MK4MDD SuperPred/target/toxic BRCA Exchange 
 Allergome CCDB GenomeCRISPR MethyCancer SuperPain BioLINCC 
 AutismKB CS-DEGs GOLD NPASS   Swiss Bioisotere BioProject 
 Biovia MDDR DART Gene DB NCATS SIMAP Colorectal Cancer Atlas 
 Biovia CMC DPD  GDKD NLDB Swiss Dock CKB 
 Binding DB Drugs@FDA GLIDA NCCN Swiss Sidechain CancerPPD 
 Binding MOAD  DT-Web GDSC NCGC SFARI Gene Clinical Codes 
 BioByte  DTOME HMDC NeuroMorpho.Org TDR Targets CVRG 
 BioLiP  DRH  HIV-1 Human Int  NIF TBDTBD C-Path 
 Brenda  DTC  HIV Drug Resistance NPACT THPdb CPRD 
 Biomodels  DrugEBIlity Human TFDB NCG6.0 TCM-ID CPIC 
 BioMart DrugMiner IntSide Neuron DB TPDB   ClinVar 
 BCNTB Bioinformatics DCDB ICGC OBO Foundry TTD ClinicalTrials.gov 
 BARD Drug Bank Integrity Oral Cancer Gene Db TAG CDSCO 
 BIG Data Centre DSigDB IQ Consortium Open Target TCMID COSMIC 
 BDGene DrugCentral Influenza Research OpenPHACTS TADB 2.0 CTRP 
 CLiBE D3R KDBI Orphanet TissGDB ChemDB HIV 
 CCD vault DBAASP KinMutBase PICKLES VKCDB DSUR   
 CTD2 Drug2gene KLIFS PhID VIPR Daily Med 
 CancerResource DGIdb Kinase SARfari PLDB WHO Drug Info DISQOVER    
 canSAR DNASU LigDig PHAROS TADB 2.0 DAAB 
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 CARLSBAD DriverDBv2 LiverAtlas PharmGKB  Decipher 
 CREDO  Disease Meth MetaADEDB PROMISCUOUS  Drug Information Portal 
 CAMPR3 EuPathDB Malaria Data PDBbind-CN DB   
                Biological databases (268)   
Drug Trials Snapshots MedLine    SPC/PIL       AbMiner    Candidate Cancer Gene Eye Gene 
Drug Safety Labeling 
Changes 
Micromedex STRIDE  (STARR) AntiJen   CarpeDB EuMMCR 
Drug consumption Db Medsafe (SMARS) Safeguard -DSRU AlzhCPI CRISPRlnc Ebola 
Disease Ontology MedWatch Sundhedsstryrelsen Allen BrainMapAtlas CirGRDB ExplorEnz 
Drug Product  Db MeSH STEP Antibody Registry  CCDS ERGR 
ENCePP NDF-RT SUSARs ABCdb  DisProt EPDnew 
EPOCRATES NAPDI T R ‘s Cortellis AHTPDB DDBJ    Fraggle 
EudraVigilance ORDO TGA (DAEN) ADPriboDB dbPTM Fusion GDB 
EAHD -CF-DB Ontobee    TCIA AntigenDB Directory of CYP P450 GenBank/WGS 
EudraCT Open FDA Trialtrove Aaindex dbSNP GlycoEpitope 
EU CTR Opportu Inf and TB Ther D TERIS AVPdb dbGaP    GLASS      
EORTC Clinical Trials Db OSB UBERON Addgene       dbVar GEO 
EFO Pharmacy One Resource USP-NF Alliance of Genome Resources     dbNP GPCRdb 
First Databank PSUR   UMLS AlloMAPS DBTSS Genome 3D 
FDA's   IND/NDA/ANDA Protect ADR DB VarCards Array Map     DIDA GTEx portal 
FAERS   PMDA          VAERS AH-DB DDMGD GENT  
GUDID PBRER      Vigibase ACLAME dbDEMC GO 
GePaRD PANDRUGS   WHO ICTRP ADHDgene DEPOD Gencode 
GHR   Physio Para for Older Adults WITHDRAWN  bioDBnet D2P2 GlyTouCan 
Gold Standard Drug DB PEPID Yellow card BUSCO ExoCarta GtRNAdb 
HC-SC (MedEffect)    PharmaVar  Brain Transcriptome ENCODE     Genome properties 
HPO    Pharmacopoeias  Bio Wiki ExAC        GENATLAS 
HEROD PILLBOX  Broad Bioimage  Enzyme Portal GermOnline 
ICD-10 PDBSE    BioMuta EMDB GPMdb 
iSAEC        PhysioBank  BDB Eidogen-Sertanty GlycoNAVI 
IB      PPMI   CPDB ECO       GeneSeeker 
IDA PDX-Finder  CASBAH Ensembl GenomeRNAi 
JH APX Guide PedAM  CAMEO  ENZYME HAMAP 
LOINC    RxNorm     CanEvolve  EGA HGNC 
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Lareb SIDER 4.1  CHOPIN Enzyme Portal Human Protein Atlas 
MedDRA SNOMED-CT  CanGem ENA HPRD 
Medicines Complete Swiss Var  CATH-Plus EMPIAR Human Genome Project 
      
Biological databases…    
HERvD Kinweb MINAS PDBTM RMDB tRFdb 
HORDE KIDFamMap MIPModDB PsychEncode RAID THPdb 
HAGR LABOME Modomics Pro kinase resource SAGD The Antibody registry 
HEMD LGICdb Metal PDB ProtChemSI Stanford Tissue Microarray Telomerase 
HPM Lipidomics Gateway NRR PHI SCDE The MaxQuant 
HIV Molecular Immu DB LncRNADisease v2.0 NPD Peptides Guide Super Hapten UbiProt 
HomloGene LOCATE NextProt PDB SysteMHC Atlas UniProtKB 
hPSCreg MGC       NURSA PRIDE SNPeffect UniProbe DB 
HGVD MITOMAP NC-IUBMB PROXiMATE Si Records ValidatorDB 
Histome miRWalk NPIDB PHOSIDA Superfamily ViralZone 
HEDD MGnify NIH 3D Print Exchange PSCDB Swiss Lipids VariO 
HGVS MHCBN NODE Proteome Isoelectric Point SSBD VDJdb 
H-InvDB MitoProteome Nextprot PED SBCDDB WebTB.org 
iPTMnet  MEROPS Noncode Plasmid starBase Wnt Db 
IEDB MultitaskProtDB NATsDB Probe SelenoDB 1000,000 Genome Project 
IUPHAR MatrixDB O-GlycBase Platinum SBKB 3did 
IMGT MPSTRUC OrthoDB PeroxisomeDB SWISS-Model 5S RNA 
InterPro MiRBase   Over gene Db PDBsum Syn Sys Net  
iProClass MRMAssayDB ORDB Pfam SynLethDB  
ImmPort Metagene Onco Db HCC Polbase Sc-PDB  
InSiGHT variant Db MitoMiner Organelle DB PolymiRTS STRENDA  
IntEnz Morphinome Organelle Genome ProtoNet SDAP  
IPD     MeDReaders Open SNP PrimerBank SYFPEITHI  
IMGT/GENE-DB MSDD OGEE ProtCID STRING  
IMGT/mAb-DB Meth HC PANTHER PPT-DB SM2miR  
IMOTA miRandola PRINTS Rhea tRNAdb  
Interferome MetalPDB PSP RoadMapepigenomics TSGene   
IDR  MicrobiomeDB PRO RBPDB topPTM  
JGI Genome portal Mitocheck Phospho-ELM RNAcentral Tp53  
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JGA Membranome Phospho 3D RegPhos TCDB  
Kinase.com MetaBase Plasma Proteome REPAIRtoire TubercuList  
Protein-Protein Interactions (54)                            Omics (60)                                                                         Pathways (38)  
APID MIPS Angiogenes Incardiome Kb AOP-KB TIGER 
BioGRID MENTHA Array Express IPD Aging Chart Transpath 
BCL2DB MATADOR Array Track KUPKB BioCyc TriForC 
CancerNet MINT BiGG LOMA Biocarta TCSBN 
ComPPI   ORTI BioSample  Metabolomics workbench DIMEdb UCSD-Nature Signaling 
Gateway  
CAZY PSMDB Biostudies MetaCore Effectopedia Wiki Pathways 
Complex Portal PPI AD 2.0 BML-NMR MutAIT Gene Network XTalkDB 
CORUM PiSITE BMRDB MitoProteome HumanCyc  
Differential Net ProtinDB BioPlex  MSigDB iPAVS  
DynaSIN ProtChemSI Biosystems MobiDB KEGG  
DIP PINT BioXpress MBROLE 2.0 MetaCyc  
DOMMINO PIMADb C-MAP  Nephroseq MetaboLights  
gpDB PSILO ccmGDB  NCI-60 (DTP) MetaMapTox  
GWIDD PIPs CEGA  OMIM Molsign  
HINT Peptide Atlas Cancer Genomic Hub Omics DI MMMP   
HIP SCOPPI CKDdb  PACdb Nrf2ome  
HPRD SKEMPI CTRP  PRIDE  PID    
H-InvDB SNAPPIView Depmap PharmacoDB PDID  
HCSGD TRIP 2.0 Disnor    READDB Pathway Commons  
HitPredict UniHI DrugSig  RefSeq PCD  
Innatedb Wiki-Pi DGVa  Rfam Path Card    
IMEx 3did DRUGSURV RGED pathDIP  
INstruct DB 2P2Idb DisGeNet SignaLink2 PathwaysWeb  
IRView  DGIdb Signor PathArt  
IntAct  Expression Atlas TB DRM Db Path Base  
I2D  FiehnLib Db TCGA REACTOME  
IIIDB  GMD  TCAG Mal Card  
iMOTdb  Gene Card Uni Carb-DB yAPOPTOSIS  
iRefWeb  HKUPP UPdb SMPDB  
KBDOCK  HMA  STITCH  
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miRTarBase  HMDB 4.0  TiPs  
Patents (9)                  Environ Exposure (30)   Animal  Alt  Methods (39)                                                                Nano Materials Toxicity (22) 
DWPI ATSDR ALTBIB OMIA CBNI  
EPO ASTDR MRLs AWIC RGD caNanoLab  
Google U.S Patents CEDI/ADI DB AnimAlt-ZEBET   SEFREC DaNa  
JAPIO CHE TDD Animal Research.info TSAR Good Nano Guide  
PATDPAFULL EAFUS Atlases-Pathology Images 3R JRC NMs Repository  
SCRIPDB EWAG-BBD AnimalTFDB US EPA Physiological 
parameters-PBPK 
NANoREG- 
eNanoMapper 
 
SureChemBL Exposome Bgee VLN NHECD  
USPTO ECHA Summaries Cellosaurus ZFIN Nano Database  
WIPO ECODRUG Cefic LRI AMBIT  Nano Safety DB  
 enviPath CEFIC LRI CEMAS  Nano techn standards  
  FDA  PAFA DBs CCLE  Nanowerk  
 heatDB CellLineNavigator  Nanodic.com  
 Haz-Map DB-ALM  Nano    
 HSDB EVA  NM registry  
 HCIS Eagle-i  NIL  
 Household Products DB EUROECOTOX Db of bioassays  NanoHub  
 HPVIS EMMA  NCL  
 IRIS FCS-free Database  Nanosafety Cluster  
 IARC Humane endpoints  NECID  
 iPiE DB Inventory of 3Rs  Kno Sources  Nano data  
 LINCS IMPC  Stat Nano  
 LactMed ICLAC  Smart Nano Tox  
 OECD-QSAR Interspecies Db    
 PHAROS IMSR     
 RiskIE IGRhCellID    
 REM DB KERIS    
 RITA LifeMap Discovery®, Cells & Tiss    
 TEDX Mouse Atlas of Gene Expression    
 TRI MPD    
 US EPA ECOTOX Non neoplastic Lesion ATLAS    
  Organ system heterogeneity DB    
988 
49 
 
 
References  
Aksoy, B.A., Dancik, V., Smith, K., Mazerik, J.N., Ji, Z., Gross, B., et al. (2017). CTD2 Dashboard: a 989 
searchable web interface to connect validated results from the Cancer Target Discovery and 990 
Development Network. Database (Oxford) 2017. DOI: 10.1093/database/bax054. 991 
 992 
Alcántara, R., Onwubiko, J., Cao, H., Matos, P.D., Cham, J.A., Jacobsen, J., et al. (2013). The EBI enzyme 993 
portal. Nucleic acids research 41, D773-D780. DOI: 10.1093/nar/gks1112. 994 
 995 
Alexander-Dann, B., Pruteanu, L.L., Oerton, E., Sharma, N., Berindan-Neagoe, I., Módos, D., et al. 996 
(2018). Developments in toxicogenomics: understanding and predicting compound-induced 997 
toxicity from gene expression data. Molecular Omics 14, 218-236. DOI: 998 
10.1039/C8MO00042E. 999 
 1000 
Alonso-Lopez, D., Gutierrez, M.A., Lopes, K.P., Prieto, C., Santamaria, R., and De Las Rivas, J. (2016). 1001 
APID interactomes: providing proteome-based interactomes with controlled quality for 1002 
multiple species and derived networks. Nucleic Acids Res 44, W529-535. DOI: 1003 
10.1093/nar/gkw363. 1004 
 1005 
Anderle, P., Duval, M., Draghici, S., Kuklin, A., Littlejohn, T.G., Medrano, J.F., et al. (2003). Gene 1006 
expression databases and data mining. Biotechniques Suppl, 36-44. 1007 
 1008 
Ayvaz, S., Horn, J., Hassanzadeh, O., Zhu, Q., Stan, J., Tatonetti, N.P., et al. (2015). Toward a complete 1009 
dataset of drug–drug interaction information from publicly available sources. Journal of 1010 
Biomedical Informatics 55, 206-217. DOI: https://doi.org/10.1016/j.jbi.2015.04.006. 1011 
 1012 
Barrett, T., Clark, K., Gevorgyan, R., Gorelenkov, V., Gribov, E., Karsch-Mizrachi, I., et al. (2012). 1013 
BioProject and BioSample databases at NCBI: facilitating capture and organization of 1014 
metadata. Nucleic Acids Research 40, D57-D63. DOI: 10.1093/nar/gkr1163. 1015 
 1016 
Barrett, T., Wilhite, S.E., Ledoux, P., Evangelista, C., Kim, I.F., Tomashevsky, M., et al. (2013). NCBI GEO: 1017 
archive for functional genomics data sets—update. Nucleic Acids Research 41, D991-D995. 1018 
DOI: 10.1093/nar/gks1193. 1019 
 1020 
Bastian, F., Parmentier, G., Roux, J., Moretti, S., Laudet, V., and Robinson-Rechavi, M. (Year). "Bgee: 1021 
Integrating and Comparing Heterogeneous Transcriptome Data Among Species": Springer 1022 
Berlin Heidelberg), 124-131. 1023 
 1024 
Bauer-Mehren, A., Furlong, L.I., and Sanz, F. (2009). Pathway databases and tools for their 1025 
exploitation: benefits, current limitations and challenges. Molecular systems biology 5, 290-1026 
290. DOI: 10.1038/msb.2009.47. 1027 
 1028 
50 
 
Beger, R.D., Young, J.F., and Fang, H. (2004). Discriminant Function Analyses of Liver-Specific 1029 
Carcinogens. Journal of Chemical Information and Computer Sciences 44, 1107-1110. DOI: 1030 
10.1021/ci0342829. 1031 
 1032 
Belinky, F., Nativ, N., Stelzer, G., Zimmerman, S., Iny Stein, T., Safran, M., et al. (2015). PathCards: 1033 
multi-source consolidation of human biological pathways. Database 2015, bav006-bav006. 1034 
DOI: 10.1093/database/bav006. 1035 
 1036 
Benigni, R., Battistelli, C.L., Bossa, C., Tcheremenskaia, O., and Crettaz, P. (2013). New perspectives in 1037 
toxicological information management, and the role of ISSTOX databases in assessing 1038 
chemical mutagenicity and carcinogenicity. Mutagenesis 28, 401-409. DOI: 1039 
10.1093/mutage/get016. 1040 
 1041 
Benson, D.A., Cavanaugh, M., Clark, K., Karsch-Mizrachi, I., Lipman, D.J., Ostell, J., et al. (2013). 1042 
GenBank. Nucleic Acids Research 41, D36-D42. DOI: 10.1093/nar/gks1195. 1043 
 1044 
Bhattacharyya, S.B. (2016). Using SNOMED CT. Singapore: Springer Singapore. 1045 
 1046 
Bianco, A.M., Marcuzzi, A., Zanin, V., Girardelli, M., Vuch, J., and Crovella, S. (2013). Database tools in 1047 
genetic diseases research. Genomics 101, 75-85. DOI: 1048 
https://doi.org/10.1016/j.ygeno.2012.11.001. 1049 
 1050 
Bitsch, A., Escher, S., Lewin, G., Melber, C., Simetska, N., and Mangelsdorf, I. (2008). RepDose and 1051 
FeDTex: Two databases focusing on systemic toxicity: First examples from analyses of 1052 
repeated dose toxicity and reprotoxicity studies. Toxicology Letters 180, S45. DOI: 1053 
https://doi.org/10.1016/j.toxlet.2008.06.598. 1054 
 1055 
Block, P., Sotriffer, C.A., Dramburg, I., and Klebe, G. (2006). AffinDB: a freely accessible database of 1056 
affinities for protein–ligand complexes from the PDB. Nucleic Acids Research 34, D522-D526. 1057 
DOI: 10.1093/nar/gkj039. 1058 
 1059 
Bower, D., Cross, K.P., Escher, S., Myatt, G.J., and Quigley, D.P. (2017). CHAPTER 9 In silico Toxicology: 1060 
An Overview of Toxicity Databases, Prediction Methodologies, and Expert Review. 1061 
Computational Systems Pharmacology and Toxicology, 209-242. DOI: 1062 
10.1039/9781782623731-00209. 1063 
 1064 
Breuer, K., Foroushani, A.K., Laird, M.R., Chen, C., Sribnaia, A., Lo, R., et al. (2013). InnateDB: systems 1065 
biology of innate immunity and beyond—recent updates and continuing curation. Nucleic 1066 
Acids Research 41, D1228-D1233. DOI: 10.1093/nar/gks1147. 1067 
 1068 
Brown, A.S., and Patel, C.J. (2017). A standard database for drug repositioning. Scientific Data 4, 1069 
170029. DOI: 10.1038/sdata.2017.29 1070 
https://www.nature.com/articles/sdata201729#supplementary-information. 1071 
 1072 
51 
 
Butkiewicz, M., Wang, Y., Bryant, S.H., Lowe, E.W., Jr., Weaver, D.C., and Meiler, J. (2017). High-1073 
Throughput Screening Assay Datasets from the PubChem Database. Chem Inform 3. 1074 
 1075 
Cases, M., Briggs, K., Steger-Hartmann, T., Pognan, F., Marc, P., Kleinöder, T., et al. (2014). The eTOX 1076 
data-sharing project to advance in silico drug-induced toxicity prediction. International journal 1077 
of molecular sciences 15, 21136-21154. DOI: 10.3390/ijms151121136. 1078 
 1079 
Cerami, E.G., Gross, B.E., Demir, E., Rodchenkov, I., Babur, Ö., Anwar, N., et al. (2011). Pathway 1080 
Commons, a web resource for biological pathway data. Nucleic Acids Research 39, D685-D690. 1081 
DOI: 10.1093/nar/gkq1039. 1082 
 1083 
Cha, Y., Erez, T., Reynolds, I.J., Kumar, D., Ross, J., Koytiger, G., et al. (2018). Drug repurposing from 1084 
the perspective of pharmaceutical companies. British Journal of Pharmacology 175, 168-180. 1085 
DOI: doi:10.1111/bph.13798. 1086 
 1087 
Chatr-Aryamontri, A., Breitkreutz, B.-J., Oughtred, R., Boucher, L., Heinicke, S., Chen, D., et al. (2015). 1088 
The BioGRID interaction database: 2015 update. Nucleic Acids Research 43, D470-D478. DOI: 1089 
10.1093/nar/gku1204. 1090 
 1091 
Chen, B., and Butte, A. (2016). Leveraging big data to transform target selection and drug discovery. 1092 
Clinical Pharmacology & Therapeutics 99, 285-297. DOI: doi:10.1002/cpt.318. 1093 
 1094 
Chen, J.H., Linstead, E., Swamidass, S.J., Wang, D., and Baldi, P. (2007). ChemDB update—full-text 1095 
search and virtual chemical space. Bioinformatics 23, 2348-2351. DOI: 1096 
10.1093/bioinformatics/btm341. 1097 
 1098 
Chen, M., Vijay, V., Shi, Q., Liu, Z., Fang, H., and Tong, W. (2011). FDA-approved drug labeling for the 1099 
study of drug-induced liver injury. Drug Discov Today 16, 697-703. DOI: 1100 
10.1016/j.drudis.2011.05.007. 1101 
 1102 
Chen, X., Ji, Z.L., Zhi, D.G., and Chen, Y.Z. (2002). CLiBE: a database of computed ligand binding energy 1103 
for ligand–receptor complexes. Computers & Chemistry 26, 661-666. DOI: 1104 
https://doi.org/10.1016/S0097-8485(02)00050-5. 1105 
 1106 
Chen, X., Yan, C.C., Zhang, X., Zhang, X., Dai, F., Yin, J., et al. (2016). Drug–target interaction prediction: 1107 
databases, web servers and computational models. Briefings in Bioinformatics 17, 696-712. 1108 
DOI: 10.1093/bib/bbv066. 1109 
 1110 
Cheng, T., Hao, M., Takeda, T., Bryant, S.H., and Wang, Y. (2017). Large-Scale Prediction of Drug-Target 1111 
Interaction: a Data-Centric Review. The AAPS Journal 19, 1264-1275. DOI: 10.1208/s12248-1112 
017-0092-6. 1113 
 1114 
Corsello, S.M., Bittker, J.A., Liu, Z., Gould, J., Mccarren, P., Hirschman, J.E., et al. (2017). The Drug 1115 
Repurposing Hub: a next-generation drug library and information resource. Nature Medicine 1116 
23, 405. DOI: 10.1038/nm.4306 1117 
52 
 
https://www.nature.com/articles/nm.4306#supplementary-information. 1118 
 1119 
Croft, D., O’kelly, G., Wu, G., Haw, R., Gillespie, M., Matthews, L., et al. (2011). Reactome: a database 1120 
of reactions, pathways and biological processes. Nucleic Acids Research 39, D691-D697. DOI: 1121 
10.1093/nar/gkq1018. 1122 
 1123 
Cronin, M. (2005). Toxicological information for use in predictive modeling: quality, sources and 1124 
databases. Boca Raton FL, USA: Taylor and Francis. 1125 
 1126 
Cronin, M.T.D., Bajot, F., Enoch, S.J., Madden, J.C., Roberts, D.W., and Schwöbel, J. (2009). The in 1127 
chemico-in silico interface: challenges for integrating experimental and computational 1128 
chemistry to identify toxicity. Altern Lab Anim 37, 513-521. 1129 
 1130 
Cronin, M.T.D. (2010). Chapter 3 Finding the Data to Develop and Evaluate (Q)SARs and Populate 1131 
Categories for Toxicity Prediction. The Royal Society of Chemistry. 1132 
 1133 
Cronin M.T.D., Richarz A.-N. (2012). The COSMOS Project: A Foundation for the Future of 1134 
Computational Modelling of Repeat Dose Toxicity. AltTox.org. DOI: AltTox.org. 1135 
 1136 
Dai, S.-X., Li, G.-H., Gao, Y.-D., and Huang, J.-F. (2016). Pharmacophore-Map-Pick: A Method to 1137 
Generate Pharmacophore Models for All Human GPCRs. Molecular Informatics 35, 81-91. DOI: 1138 
doi:10.1002/minf.201500075. 1139 
 1140 
Davis, A.P., King, B.L., Mockus, S., Murphy, C.G., Saraceni-Richards, C., Rosenstein, M., et al. (2011). 1141 
The Comparative Toxicogenomics Database: update 2011. Nucleic Acids Res 39, D1067-1072. 1142 
DOI: 10.1093/nar/gkq813. 1143 
 1144 
Dong, J., Wang, N.-N., Yao, Z.-J., Zhang, L., Cheng, Y., Ouyang, D., et al. (2018a). ADMETlab: a platform 1145 
for systematic ADMET evaluation based on a comprehensively collected ADMET database. 1146 
Journal of cheminformatics 10, 29-29. DOI: 10.1186/s13321-018-0283-x. 1147 
 1148 
Dong, J., Wang, N., Yao, Z., Zhang, L., Cheng, Y., Ouyang, D., et al. (2018b). ADMETlab: a platform for 1149 
systematic ADMET evaluation based on a comprehensively collected ADMET database. 1150 
 1151 
Douguet, D. (2010). e-LEA3D: a computational-aided drug design web server. Nucleic acids research 1152 
38, W615-621. DOI: 10.1093/nar/gkq322. 1153 
 1154 
Edgar, R., Mazor, Y., Rinon, A., Blumenthal, J., Golan, Y., Buzhor, E., et al. (2013). LifeMap Discovery™: 1155 
the embryonic development, stem cells, and regenerative medicine research portal. PloS one 1156 
8, e66629-e66629. DOI: 10.1371/journal.pone.0066629. 1157 
 1158 
Ekins, S., Freundlich, J.S., Choi, I., Sarker, M., and Talcott, C. (2011). Computational databases, pathway 1159 
and cheminformatics tools for tuberculosis drug discovery. Trends in microbiology 19, 65-74. 1160 
DOI: 10.1016/j.tim.2010.10.005. 1161 
 1162 
53 
 
Ekins, S., Nikolsky, Y., and Nikolskaya, T. (2005). Techniques: Application of systems biology to 1163 
absorption, distribution, metabolism, excretion and toxicity. Trends in Pharmacological 1164 
Sciences 26, 202-209. DOI: https://doi.org/10.1016/j.tips.2005.02.006. 1165 
 1166 
Ekins, S., and Williams, A.J. (2010). Precompetitive preclinical ADME/Tox data: set it free on the web 1167 
to facilitate computational model building and assist drug development. Lab on a Chip 10, 13-1168 
22. DOI: 10.1039/B917760B. 1169 
 1170 
Embry, M.R., Bachman, A.N., Bell, D.R., Boobis, A.R., Cohen, S.M., Dellarco, M., et al. (2014). Risk 1171 
assessment in the 21st century: Roadmap and matrix. Critical Reviews in Toxicology 44, 6-16. 1172 
DOI: 10.3109/10408444.2014.931924. 1173 
 1174 
Fabian, E., Bordag, N., Herold, M., Kamp, H., Krennrich, G., Looser, R., et al. (2016). Metabolite profiles 1175 
of rats in repeated dose toxicological studies after oral and inhalative exposure. Toxicology 1176 
Letters 255, 11-23. DOI: https://doi.org/10.1016/j.toxlet.2016.05.003. 1177 
 1178 
Fang, H., Su, Z., Wang, Y., Miller, A., Liu, Z., Howard, P., et al. (2014). Exploring the FDA Adverse Event 1179 
Reporting System (FAERS) to Generate Hypotheses for Disease Monitoring. Clinical 1180 
pharmacology and therapeutics 95, 496-498. DOI: 10.1038/clpt.2014.17. 1181 
 1182 
 1183 
Fleischmann, A., Darsow, M., Degtyarenko, K., Fleischmann, W., Boyce, S., Axelsen, K.B., et al. (2004). 1184 
IntEnz, the integrated relational enzyme database. Nucleic Acids Research 32, D434-D437. 1185 
DOI: 10.1093/nar/gkh119. 1186 
 1187 
Fonger, G.C. (1995). Hazardous substances data bank (HSDB) as a source of environmental fate 1188 
information on chemicals. Toxicology 103, 137-145. DOI: https://doi.org/10.1016/0300-1189 
483X(95)03145-6. 1190 
 1191 
Fostel, J., Van Someren, E., Pronk, T., Pennings, J., Schmeits, P., Shao, J., et al. (2014). Chapter 6.2 - 1192 
Toxicogenomics and Systems Toxicology Databases and Resources: Chemical Effects in 1193 
Biological Systems (CEBS) and Data Integration by Applying Models on Design and Safety 1194 
(DIAMONDS). San Diego: Academic Press. 1195 
 1196 
Fotis, C., Antoranz, A., Hatziavramidis, D., Sakellaropoulos, T., and Alexopoulos, L.G. (2018). Network-1197 
based technologies for early drug discovery. Drug Discovery Today 23, 626-635. DOI: 1198 
https://doi.org/10.1016/j.drudis.2017.12.001. 1199 
 1200 
Fourches, D., Muratov, E., and Tropsha, A. (2010). Trust, But Verify: On the Importance of Chemical 1201 
Structure Curation in Cheminformatics and QSAR Modeling Research. Journal of Chemical 1202 
Information and Modeling 50, 1189-1204. DOI: 10.1021/ci100176x. 1203 
 1204 
Fouretier, A., Malriq, A., and Bertram, D.J.P.M. (2016). Open Access Pharmacovigilance Databases: 1205 
Analysis of 11 Databases. 30, 221-231. DOI: 10.1007/s40290-016-0146-6. 1206 
 1207 
54 
 
Gaieb, Z., Liu, S., Gathiaka, S., Chiu, M., Yang, H., Shao, C., et al. (2018). D3R Grand Challenge 2: blind 1208 
prediction of protein–ligand poses, affinity rankings, and relative binding free energies. 1209 
Journal of Computer-Aided Molecular Design 32, 1-20. DOI: 10.1007/s10822-017-0088-4. 1210 
 1211 
Gathiaka, S., Liu, S., Chiu, M., Yang, H., Stuckey, J.A., Kang, Y.N., et al. (2016). D3R grand challenge 1212 
2015: Evaluation of protein–ligand pose and affinity predictions. Journal of Computer-Aided 1213 
Molecular Design 30, 651-668. DOI: 10.1007/s10822-016-9946-8. 1214 
 1215 
Gaulton, A., Hersey, A., Nowotka, M., Bento, A.P., Chambers, J., Mendez, D., et al. (2017). The ChEMBL 1216 
database in 2017. Nucleic Acids Research 45, D945-D954. DOI: 10.1093/nar/gkw1074. 1217 
 1218 
Gilson, M.K., Liu, T., Baitaluk, M., Nicola, G., Hwang, L., and Chong, J. (2016). BindingDB in 2015: A 1219 
public database for medicinal chemistry, computational chemistry and systems 1220 
pharmacology. Nucleic Acids Res 44, D1045-1053. DOI: 10.1093/nar/gkv1072. 1221 
 1222 
Goede, A., Dunkel, M., Mester, N., Frommel, C., and Preissner, R. (2005). SuperDrug: a conformational 1223 
drug database. Bioinformatics 21, 1751-1753. DOI: 10.1093/bioinformatics/bti295. 1224 
 1225 
Gohlke, B.O., Nickel, J., Otto, R., Dunkel, M., and Preissner, R. (2016). CancerResource--updated 1226 
database of cancer-relevant proteins, mutations and interacting drugs. Nucleic Acids Res 44, 1227 
D932-937. DOI: 10.1093/nar/gkv1283. 1228 
 1229 
Gohlke, B.O., Preissner, R., and Preissner, S. (2014). SuperPain--a resource on pain-relieving 1230 
compounds targeting ion channels. Nucleic Acids Res 42, D1107-1112. DOI: 1231 
10.1093/nar/gkt1176. 1232 
 1233 
González-Medina, M., Naveja, J.J., Sánchez-Cruz, N., and Medina-Franco, J.L. (2017). Open 1234 
chemoinformatic resources to explore the structure, properties and chemical space of 1235 
molecules. RSC Advances 7, 54153-54163. DOI: 10.1039/C7RA11831G. 1236 
 1237 
Gray, K.A., Seal, R.L., Tweedie, S., Wright, M.W., and Bruford, E.A. (2016). A review of the new HGNC 1238 
gene family resource. Hum Genomics 10, 6. DOI: 10.1186/s40246-016-0062-6. 1239 
 1240 
Griffith, M., Griffith, O.L., Coffman, A.C., Weible, J.V., Mcmichael, J.F., Spies, N.C., et al. (2013). DGIdb: 1241 
mining the druggable genome. Nature Methods 10, 1209. DOI: 10.1038/nmeth.2689 1242 
https://www.nature.com/articles/nmeth.2689#supplementary-information. 1243 
 1244 
Grune, B., Herrmann, S., Dorendahl, A., Skolik, S., Behnck-Knoblau, S., Box, R., et al. (2000). [The ZEBET 1245 
database on alternative methods to animal experiments in the Internet--a concrete 1246 
contribution to the protection of animals]. Altex 17, 127-133. 1247 
 1248 
Gunther, S., Kuhn, M., Dunkel, M., Campillos, M., Senger, C., Petsalaki, E., et al. (2008). SuperTarget 1249 
and Matador: resources for exploring drug-target relationships. Nucleic Acids Res 36, D919-1250 
922. DOI: 10.1093/nar/gkm862. 1251 
55 
 
 1252 
Hachad, H., Overby, C.L., Argon, S., Yeung, C.K., Ragueneau-Majlessi, I., and Levy, R.H. (2011). e-1253 
PKGene: a knowledge-based research tool for analysing the impact of genetics on drug 1254 
exposure. Human genomics 5, 506-515. DOI: 10.1186/1479-7364-5-5-506. 1255 
 1256 
Hachad, H., Ragueneau-Majlessi, I., and Levy, R.H. (2010). A useful tool for drug interaction evaluation: 1257 
the University of Washington Metabolism and Transport Drug Interaction Database. Human 1258 
genomics 5, 61-72. DOI: 10.1186/1479-7364-5-1-61. 1259 
 1260 
Hamosh, A., Scott, A.F., Amberger, J.S., Bocchini, C.A., and Mckusick, V.A. (2005). Online Mendelian 1261 
Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic 1262 
Acids Research 33, D514-D517. DOI: 10.1093/nar/gki033. 1263 
 1264 
Hartung, T., Fitzgerald, R.E., Jennings, P., Mirams, G.R., Peitsch, M.C., Rostami-Hodjegan, A., et al. 1265 
(2017). Systems Toxicology: Real World Applications and Opportunities. Chemical Research in 1266 
Toxicology 30, 870-882. DOI: 10.1021/acs.chemrestox.7b00003. 1267 
 1268 
Hay, D.L., Garelja, M.L., Poyner, D.R., and Walker, C.S. (2018). Update on the pharmacology of 1269 
calcitonin/CGRP family of peptides: IUPHAR Review 25. Br J Pharmacol 175, 3-17. DOI: 1270 
10.1111/bph.14075. 1271 
 1272 
Heifets, A., and Jurisica, I. (2012). SCRIPDB: a portal for easy access to syntheses, chemicals and 1273 
reactions in patents. Nucleic acids research 40, D428-D433. DOI: 10.1093/nar/gkr919. 1274 
 1275 
Hendrickx, D.M., Aerts, H.J.W.L., Caiment, F., Clark, D., Ebbels, T.M.D., Evelo, C.T., et al. (2015). diXa: 1276 
a data infrastructure for chemical safety assessment. Bioinformatics (Oxford, England) 31, 1277 
1505-1507. DOI: 10.1093/bioinformatics/btu827. 1278 
 1279 
Hermjakob, H., Montecchi-Palazzi, L., Lewington, C., Mudali, S., Kerrien, S., Orchard, S., et al. (2004). 1280 
IntAct: an open source molecular interaction database. Nucleic Acids Research 32, D452-D455. 1281 
DOI: 10.1093/nar/gkh052. 1282 
 1283 
Hersey, A., Chambers, J., Bellis, L., Patrícia Bento, A., Gaulton, A., and Overington, J.P. (2015). Chemical 1284 
databases: curation or integration by user-defined equivalence? Drug Discovery Today: 1285 
Technologies 14, 17-24. DOI: https://doi.org/10.1016/j.ddtec.2015.01.005. 1286 
 1287 
Hoofnagle, J.H., Serrano, J., Knoben, J.E., and Navarro, V.J. (2013). LiverTox: A website on drug-induced 1288 
liver injury. Hepatology 57, 873-874. DOI: doi:10.1002/hep.26175. 1289 
 1290 
Humphreys, B.L., Lindberg, D.A., Schoolman, H.M., and Barnett, G.O. (1998). The Unified Medical 1291 
Language System: an informatics research collaboration. Journal of the American Medical 1292 
Informatics Association : JAMIA 5, 1-11. DOI: 10.1136/jamia.1998.0050001. 1293 
 1294 
56 
 
Igarashi, Y., Nakatsu, N., Yamashita, T., Ono, A., Ohno, Y., Urushidani, T., et al. (2015). Open TG-GATEs: 1295 
a large-scale toxicogenomics database. Nucleic Acids Res 43, D921-927. DOI: 1296 
10.1093/nar/gku955. 1297 
 1298 
Ito, J.-I., Tabei, Y., Shimizu, K., Tsuda, K., and Tomii, K. (2012). PoSSuM: a database of similar protein-1299 
ligand binding and putative pockets. Nucleic acids research 40, D541-D548. DOI: 1300 
10.1093/nar/gkr1130. 1301 
 1302 
Jassal, B., O’donovan, C., Rowland, F., Holliday, G.L., Kleywegt, G.J., Hermjakob, H., et al. (2012). The 1303 
EBI enzyme portal. Nucleic Acids Research 41, D773-D780. DOI: 10.1093/nar/gks1112 %J 1304 
Nucleic Acids Research. 1305 
 1306 
Jeliazkova, N., Chomenidis, C., Doganis, P., Fadeel, B., Grafström, R., Hardy, B., et al. (2015). The 1307 
eNanoMapper database for nanomaterial safety information. Beilstein Journal of 1308 
Nanotechnology 6, 1609-1634. DOI: 10.3762/bjnano.6.165. 1309 
 1310 
Ji, Z.L., Han, L.Y., Yap, C.W., Sun, L.Z., Chen, X., and Chen, Y.Z. (2003a). Drug Adverse Reaction Target 1311 
Database (DART). Drug Safety 26, 685-690. DOI: 10.2165/00002018-200326100-00002. 1312 
 1313 
Ji, Z.L., Sun, L.Z., Chen, X., Zheng, C.J., Yao, L.X., Han, L.Y., et al. (2003b). Internet resources for proteins 1314 
associated with drug therapeutic effects, adverse reactions and ADME. Drug Discovery Today 1315 
8, 526-529. DOI: https://doi.org/10.1016/S1359-6446(03)02742-9. 1316 
 1317 
Johnson, B.L. (1995). ATSDR's information databases to support human health risk assessment of 1318 
hazardous substances. Toxicology Letters 79, 11-16. DOI: https://doi.org/10.1016/0378-1319 
4274(95)03351-K. 1320 
 1321 
Jonsdottir, S.O., Jorgensen, F.S., and Brunak, S. (2005). Prediction methods and databases within 1322 
chemoinformatics: emphasis on drugs and drug candidates. Bioinformatics 21, 2145-2160. 1323 
DOI: 10.1093/bioinformatics/bti314. 1324 
 1325 
Judson, R. (2010). Public databases supporting computational toxicology. J Toxicol Environ Health B 1326 
Crit Rev 13, 218-231. DOI: 10.1080/10937404.2010.483937. 1327 
 1328 
Judson, R., Richard, A., Dix, D., Houck, K., Elloumi, F., Martin, M., et al. (2008). ACToR — Aggregated 1329 
Computational Toxicology Resource. Toxicology and Applied Pharmacology 233, 7-13. DOI: 1330 
https://doi.org/10.1016/j.taap.2007.12.037. 1331 
 1332 
Kale, N.S., Haug, K., Conesa, P., Jayseelan, K., Moreno, P., Rocca-Serra, P., et al. (2016). MetaboLights: 1333 
An Open-Access Database Repository for Metabolomics Data. Current Protocols in 1334 
Bioinformatics 53, 14.13.11-14.13.18. DOI: doi:10.1002/0471250953.bi1413s53. 1335 
 1336 
Kanehisa, M., and Goto, S. (2000). KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids 1337 
Research 28, 27-30. DOI: 10.1093/nar/28.1.27. 1338 
57 
 
 1339 
Katsila, T., Spyroulias, G.A., Patrinos, G.P., and Matsoukas, M.-T. (2016). Computational approaches in 1340 
target identification and drug discovery. Computational and Structural Biotechnology Journal 1341 
14, 177-184. DOI: https://doi.org/10.1016/j.csbj.2016.04.004. 1342 
 1343 
King, Z.A., Lu, J., Dräger, A., Miller, P., Federowicz, S., Lerman, J.A., et al. (2016). BiGG Models: A 1344 
platform for integrating, standardizing and sharing genome-scale models. Nucleic Acids 1345 
Research 44, D515-D522. DOI: 10.1093/nar/gkv1049. 1346 
 1347 
Kiyosawa, N., Shiwaku, K., Hirode, M., Omura, K., Uehara, T., Shimizu, T., et al. (2006). UTILIZATION OF 1348 
A ONE-DIMENSIONAL SCORE FOR SURVEYING CHEMICAL-INDUCED CHANGES IN EXPRESSION 1349 
LEVELS OF MULTIPLE BIOMARKER GENE SETS USING A LARGE-SCALE TOXICOGENOMICS 1350 
DATABASE. The Journal of Toxicological Sciences 31, 433-448. DOI: 10.2131/jts.31.433. 1351 
 1352 
Klimisch, H.J., Andreae, M., and Tillmann, U. (1997). A Systematic Approach for Evaluating the Quality 1353 
of Experimental Toxicological and Ecotoxicological Data. Regulatory Toxicology and 1354 
Pharmacology 25, 1-5. DOI: https://doi.org/10.1006/rtph.1996.1076. 1355 
 1356 
Kongsbak, K., Hadrup, N., Audouze, K., and Vinggaard, A.M. (2014). Applicability of Computational 1357 
Systems Biology in Toxicology. Basic & Clinical Pharmacology & Toxicology 115, 45-49. DOI: 1358 
doi:10.1111/bcpt.12216. 1359 
 1360 
Koscielny, G., An, P., Carvalho-Silva, D., Cham, J.A., Fumis, L., Gasparyan, R., et al. (2017). Open Targets: 1361 
a platform for therapeutic target identification and validation. Nucleic Acids Research 45, 1362 
D985-D994. DOI: 10.1093/nar/gkw1055. 1363 
 1364 
Koutsoukas, A., Simms, B., Kirchmair, J., Bond, P.J., Whitmore, A.V., Zimmer, S., et al. (2011). From in 1365 
silico target prediction to multi-target drug design: Current databases, methods and 1366 
applications. Journal of Proteomics 74, 2554-2574. 1367 
DOI:https://doi.org/10.1016/j.jprot.2011.05.011. 1368 
 1369 
Kroetz, D.L., Yee, S.W., and Giacomini, K.M. (2009). The Pharmacogenomics of Membrane 1370 
Transporters Project: Research at the Interface of Genomics and Transporter Pharmacology. 1371 
Clinical Pharmacology & Therapeutics 87, 109-116. DOI: 10.1038/clpt.2009.226. 1372 
 1373 
Kuang, X., Han, J.G., Zhao, N., Pang, B., Shyu, C.-R., and Korkin, D. (2012). DOMMINO: a database of 1374 
macromolecular interactions. Nucleic Acids Research 40, D501-D506. DOI: 1375 
10.1093/nar/gkr1128. 1376 
 1377 
Kuhn, M., Letunic, I., Jensen, L.J., and Bork, P. (2016). The SIDER database of drugs and side effects. 1378 
Nucleic Acids Research 44, D1075-D1079. DOI: 10.1093/nar/gkv1075. 1379 
 1380 
Kumar, R., Chaudhary, K., Gupta, S., Singh, H., Kumar, S., Gautam, A., et al. (2013). CancerDR: cancer 1381 
drug resistance database. Scientific reports 3, 1445. DOI: 10.1038/srep01445. 1382 
 1383 
58 
 
Kundrotas, P.J., Zhu, Z., and Vakser, I.A. (2012). GWIDD: a comprehensive resource for genome-wide 1384 
structural modeling of protein-protein interactions. Hum Genomics 6, 7. DOI: 10.1186/1479-1385 
7364-6-7. 1386 
 1387 
Lacroix-Fralish, M.L., Ledoux, J.B., and Mogil, J.S. (2007). The Pain Genes Database: An interactive web 1388 
browser of pain-related transgenic knockout studies. Pain 131, 3.e1-3.e4. DOI: 1389 
https://doi.org/10.1016/j.pain.2007.04.041. 1390 
 1391 
Lamb, J., Crawford, E.D., Peck, D., Modell, J.W., Blat, I.C., Wrobel, M.J., et al. (2006). The Connectivity 1392 
Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease. 1393 
Science 313, 1929-1935. DOI: 10.1126/science.1132939. 1394 
 1395 
Lappalainen, I., Almeida-King, J., Kumanduri, V., Senf, A., Spalding, J.D., Ur-Rehman, S., et al. (2015). 1396 
The European Genome-phenome Archive of human data consented for biomedical research. 1397 
Nature genetics 47, 692-695. DOI: 10.1038/ng.3312. 1398 
 1399 
Legehar, A., Xhaard, H., and Ghemtio, L. (2016). IDAAPM: integrated database of ADMET and adverse 1400 
effects of predictive modeling based on FDA approved drug data. Journal of Cheminformatics 1401 
8, 33. DOI: 10.1186/s13321-016-0141-7. 1402 
 1403 
Leroy, B., Fournier, J.L., Ishioka, C., Monti, P., Inga, A., Fronza, G., et al. (2013). The TP53 website: an 1404 
integrative resource centre for the TP53 mutation database and TP53 mutant analysis. Nucleic 1405 
Acids Res 41, D962-969. DOI: 10.1093/nar/gks1033. 1406 
 1407 
Liebsch, M., Grune, B., Seiler, A., Butzke, D., Oelgeschläger, M., Pirow, R., et al. (2011). Alternatives to 1408 
animal testing: current status and future perspectives. Archives of Toxicology 85, 841-858. 1409 
DOI: 10.1007/s00204-011-0718-x. 1410 
 1411 
Lindquist, M. (2008). VigiBase, the WHO Global ICSR Database System: Basic Facts. Drug Information 1412 
Journal 42, 409-419. DOI: 10.1177/009286150804200501. 1413 
 1414 
Liu, C., Su, J., Yang, F., Wei, K., Ma, J., and Zhou, X. (2015). Compound signature detection on LINCS 1415 
L1000 big data. Mol Biosyst 11, 714-722. DOI: 10.1039/c4mb00677a. 1416 
 1417 
Lo surdo, P., Calderone, A., Iannuccelli, M., Licata, L., Peluso, D., Castagnoli, L., et al. (2018). DISNOR: 1418 
a disease network open resource. Nucleic Acids Research 46, D527-D534. DOI: 1419 
10.1093/nar/gkx876. 1420 
 1421 
Loging, W., Rodriguez-Esteban, R., Hill, J., Freeman, T., and Miglietta, J. (2011). 1422 
Cheminformatic/bioinformatic analysis of large corporate databases: Application to drug 1423 
repurposing. Drug Discovery Today: Therapeutic Strategies 8, 109-116. DOI: 1424 
https://doi.org/10.1016/j.ddstr.2011.06.004. 1425 
 1426 
Luo, G., Shen, Y., Yang, L., Lu, A., and Xiang, Z. (2017). A review of drug-induced liver injury databases. 1427 
Archives of Toxicology 91, 3039-3049. DOI: 10.1007/s00204-017-2024-8. 1428 
59 
 
 1429 
Madden, J.C. (2013). Chapter 5 Sources of Chemical Information, Toxicity Data and Assessment of Their 1430 
Quality. The Royal Society of Chemistry. 1431 
 1432 
Madden, J.C., Pawar, G., Cronin, M.T.D., Webb, S., Tan, Y.-M., and Paini, A. (2019). In Silico Resources 1433 
to Assist in the Development and Evaluation of Physiologically-Based Kinetic Models. 1434 
Computational Toxicology. DOI: https://doi.org/10.1016/j.comtox.2019.03.001. 1435 
 1436 
Maimon, O., and Browarnik, A. (2010). NHECD - Nano Health and Environmental Commented 1437 
Database. Boston, MA: Springer US. 1438 
 1439 
Mak, L., Marcus, D., Howlett, A., Yarova, G., Duchateau, G., Klaffke, W., et al. (2015). Metrabase: a 1440 
cheminformatics and bioinformatics database for small molecule transporter data analysis 1441 
and (Q)SAR modeling. Journal of Cheminformatics 7, 31. DOI: 10.1186/s13321-015-0083-5. 1442 
 1443 
Mathias, S.L., Hines-Kay, J., Yang, J.J., Zahoransky-Kohalmi, G., Bologa, C.G., Ursu, O., et al. (2013). The 1444 
CARLSBAD Database: A Confederated Database of Chemical Bioactivities. Database: The 1445 
Journal of Biological Databases and Curation 2013, bat044. DOI: 10.1093/database/bat044. 1446 
 1447 
Meng, X., Wang, J., Yuan, C., Li, X., Zhou, Y., Hofestädt, R., et al. (2015). CancerNet: a database for 1448 
decoding multilevel molecular interactions across diverse cancer types. Oncogenesis 4, e177. 1449 
DOI: 10.1038/oncsis.2015.40. 1450 
 1451 
Morley, G. (2014). Adverse event reporting: A brief overview of MedDRA. Medical Writing 23, 113-1452 
116. DOI: 10.1179/2047480614Z.000000000208. 1453 
 1454 
Morrissey, K.M., Wen, C.C., Johns, S.J., Zhang, L., Huang, S.M., and Giacomini, K.M. (2012). The UCSF-1455 
FDA TransPortal: A Public Drug Transporter Database. Clinical Pharmacology & Therapeutics 1456 
92, 545-546. DOI: 10.1038/clpt.2012.44. 1457 
 1458 
Nasko, D.J., Koren, S., Phillippy, A.M., and Treangen, T.J. (2018). RefSeq database growth influences 1459 
the accuracy of k-mer-based species identification. bioRxiv. DOI: 10.1101/304972. 1460 
 1461 
Natsume-Kitatani, Y., Nyström-Persson, J., Igarashi, Y., Satoh, D., and Mizuguchi, K. (2017). Integrated 1462 
toxicogenomics analysis with Toxygates for inferring molecular mechanisms. Genomics and 1463 
Computational Biology 3, e37. DOI: 10.18547/gcb.2017.vol3.iss1.e37. 1464 
 1465 
Nelson, S.J., Johnston, W.D., and Humphreys, B.L. (2001). Relationships in Medical Subject Headings 1466 
(MeSH). Dordrecht: Springer Netherlands. 1467 
 1468 
Nguyen, D.-T., Mathias, S., Bologa, C., Brunak, S., Fernandez, N., Gaulton, A., et al. (2017). Pharos: 1469 
Collating protein information to shed light on the druggable genome. Nucleic acids research 1470 
45, D995-D1002. DOI: 10.1093/nar/gkw1072. 1471 
 1472 
Nicola, G., Liu, T., and Gilson, M.K. (2012). Public domain databases for medicinal chemistry. Journal 1473 
of medicinal chemistry 55, 6987-7002. DOI: 10.1021/jm300501t. 1474 
60 
 
 1475 
Nyström-Persson, J., Igarashi, Y., Ito, M., Morita, M., Nakatsu, N., Yamada, H., et al. (2013). Toxygates: 1476 
interactive toxicity analysis on a hybrid microarray and linked data platform. Bioinformatics 1477 
29, 3080-3086. DOI: 10.1093/bioinformatics/btt531 %J Bioinformatics. 1478 
 1479 
Okuno, Y., Yang, J., Taneishi, K., Yabuuchi, H., and Tsujimoto, G. (2006). GLIDA: GPCR-ligand database 1480 
for chemical genomic drug discovery. Nucleic Acids Research 34, D673-D677. DOI: 1481 
10.1093/nar/gkj028. 1482 
 1483 
Opassi, G., Gesù, A., and Massarotti, A. (2018). The hitchhiker’s guide to the chemical-biological galaxy. 1484 
Drug Discovery Today 23, 565-574. DOI:https://doi.org/10.1016/j.drudis.2018.01.007. 1485 
 1486 
Oprea, T.I., and Tropsha, A. (2006). Target, chemical and bioactivity databases – integration is key. 1487 
Drug Discovery Today: Technologies 3, 357-365. 1488 
DOI:https://doi.org/10.1016/j.ddtec.2006.12.003. 1489 
 1490 
Ozawa, N., Shimizu, T., Morita, R., Yokono, Y., Ochiai, T., Munesada, K., et al. (2004). Transporter 1491 
database, TP-Search: a web-accessible comprehensive database for research in 1492 
pharmacokinetics of drugs. Pharm Res 21, 2133-2134. 1493 
 1494 
Pándy-Szekeres, G., Munk, C., Tsonkov, T.M., Mordalski, S., Harpsøe, K., Hauser, A.S., et al. (2018). 1495 
GPCRdb in 2018: adding GPCR structure models and ligands. Nucleic Acids Research 46, D440-1496 
D446. DOI: 10.1093/nar/gkx1109. 1497 
 1498 
Papadatos, G., Davies, M., Dedman, N., Chambers, J., Gaulton, A., Siddle, J., et al. (2016). SureChEMBL: 1499 
a large-scale, chemically annotated patent document database. Nucleic Acids Research 44, 1500 
D1220-D1228. DOI: 10.1093/nar/gkv1253. 1501 
 1502 
Papadopoulos, T., Krochmal, M., Cisek, K., Fernandes, M., Husi, H., Stevens, R., et al. (2016). Omics 1503 
databases on kidney disease: where they can be found and how to benefit from them. Clinical 1504 
Kidney Journal 9, 343-352. DOI: 10.1093/ckj/sfv155. 1505 
 1506 
Parkinson, H., Kapushesky, M., Shojatalab, M., Abeygunawardena, N., Coulson, R., Farne, A., et al. 1507 
(2007). ArrayExpress--a public database of microarray experiments and gene expression 1508 
profiles. Nucleic acids research 35, D747-D750. DOI: 10.1093/nar/gkl995. 1509 
 1510 
Pathak, J., and Chute, C.G. (2010). Analyzing categorical information in two publicly available drug 1511 
terminologies: RxNorm and NDF-RT. J Am Med Inform Assoc 17, 432-439. DOI: 1512 
10.1136/jamia.2009.001289. 1513 
 1514 
Peach, M.L., Zakharov, A.V., Liu, R., Pugliese, A., Tawa, G., Wallqvist, A., et al. (2012). Computational 1515 
tools and resources for metabolism-related property predictions. 1. Overview of publicly 1516 
available (free and commercial) databases and software. 4, 1907-1932. DOI: 1517 
10.4155/fmc.12.150. 1518 
 1519 
61 
 
Pence, H.E., and Williams, A. (2010). ChemSpider: An Online Chemical Information Resource. Journal 1520 
of Chemical Education 87, 1123-1124. DOI: 10.1021/ed100697w. 1521 
 1522 
Perez-Riverol, Y., Bai, M., Da Veiga Leprevost, F., Squizzato, S., Park, Y.M., Haug, K., et al. (2017). 1523 
Discovering and linking public omics data sets using the Omics Discovery Index. Nature 1524 
Biotechnology 35, 406. DOI: 10.1038/nbt.3790 1525 
https://www.nature.com/articles/nbt.3790#supplementary-information. 1526 
 1527 
Piñero, J., Bravo, À., Queralt-Rosinach, N., Gutiérrez-Sacristán, A., Deu-Pons, J., Centeno, E., et al. 1528 
(2017). DisGeNET: a comprehensive platform integrating information on human disease-1529 
associated genes and variants. Nucleic Acids Research 45, D833-D839. DOI: 1530 
10.1093/nar/gkw943. 1531 
 1532 
Placzek, S., Schomburg, I., Chang, A., Jeske, L., Ulbrich, M., Tillack, J., et al. (2017). BRENDA in 2017: 1533 
new perspectives and new tools in BRENDA. Nucleic acids research 45, D380-D388. DOI: 1534 
10.1093/nar/gkw952. 1535 
 1536 
Polen, H.H., Zapantis, A., Clauson, K.A., Jebrock, J., and Paris, M. (2008). Ability of online drug 1537 
databases to assist in clinical decision-making with infectious disease therapies. BMC 1538 
Infectious Diseases 8, 153. DOI: 10.1186/1471-2334-8-153. 1539 
 1540 
Postigo, R., Brosch, S., Slattery, J., Van Haren, A., Dogné, J.-M., Kurz, X., et al. (2018). EudraVigilance 1541 
Medicines Safety Database: Publicly Accessible Data for Research and Public Health 1542 
Protection. Drug Safety 41, 665-675. DOI: 10.1007/s40264-018-0647-1. 1543 
 1544 
Przybylak, K.R., Madden, J.C., Covey-Crump, E., Gibson, L., Barber, C., Patel, M., et al. (2018). 1545 
Characterisation of data resources for in silico modelling: benchmark datasets for ADME 1546 
properties. Expert Opinion on Drug Metabolism & Toxicology 14, 169-181. DOI: 1547 
10.1080/17425255.2017.1316449. 1548 
 1549 
 1550 
Rana, B.K., Bourne, P.E., and Insel, P.A. (2012). Receptor Databases and Computational Websites for 1551 
Ligand Binding. Totowa, NJ: Humana Press. 1552 
 1553 
Rappaport, N., Twik, M., Nativ, N., Stelzer, G., Bahir, I., Stein, T.I., et al. (2014). MalaCards: A 1554 
Comprehensive Automatically-Mined Database of Human Diseases. Current Protocols in 1555 
Bioinformatics 47, 1.24.21-21.24.19. DOI: 10.1002/0471250953.bi0124s47. 1556 
 1557 
Rigden, D.J., Fernández-Suárez, X.M., and Galperin, M.Y. (2016). The 2016 database issue of Nucleic 1558 
Acids Research and an updated molecular biology database collection. Nucleic Acids Research 1559 
44, D1-D6. DOI: 10.1093/nar/gkv1356. 1560 
 1561 
Rosen, N., Chalifa-Caspi, V., Shmueli, O., Adato, A., Lapidot, M., Stampnitzky, J., et al. (2003). GeneLoc: 1562 
exon-based integration of human genome maps. Bioinformatics 19, i222-i224. DOI: 1563 
10.1093/bioinformatics/btg1030. 1564 
62 
 
 1565 
Rual, J.F., Venkatesan, K., Hao, T., Hirozane-Kishikawa, T., Dricot, A., Li, N., et al. (2005). Towards a 1566 
proteome-scale map of the human protein-protein interaction network. Nature 437, 1173-1567 
1178. DOI: 10.1038/nature04209. 1568 
 1569 
Ruddigkeit, L., Blum, L.C., and Reymond, J.-L. (2013). Visualization and Virtual Screening of the 1570 
Chemical Universe Database GDB-17. Journal of Chemical Information and Modeling 53, 56-1571 
65. DOI: 10.1021/ci300535x. 1572 
 1573 
Safran, M., Dalah, I., Alexander, J., Rosen, N., Iny Stein, T., Shmoish, M., et al. (2010). GeneCards 1574 
Version 3: the human gene integrator. Database 2010, baq020-baq020. DOI: 1575 
10.1093/database/baq020. 1576 
 1577 
Sakuratani, Y., Zhang, H.Q., Nishikawa, S., Yamazaki, K., Yamada, T., Yamada, J., et al. (2013). Hazard 1578 
Evaluation Support System (HESS) for predicting repeated dose toxicity using toxicological 1579 
categories. SAR and QSAR in Environmental Research 24, 351-363. DOI: 1580 
10.1080/1062936X.2013.773375. 1581 
 1582 
Sam, S.A., Teel, J., Tegge, A.N., Bharadwaj, A., and Murali, T.M. (2017). XTalkDB: a database of signaling 1583 
pathway crosstalk. Nucleic Acids Research 45, D432-D439. DOI: 10.1093/nar/gkw1037. 1584 
 1585 
Sanz, F., Pognan, F., Steger-Hartmann, T., Díaz, C., Etox, Cases, M., et al. (2017). Legacy data sharing 1586 
to improve drug safety assessment: the eTOX project. Nature Reviews Drug Discovery 16, 811. 1587 
DOI: 10.1038/nrd.2017.177 https://www.nature.com/articles/nrd.2017.177#supplementary-1588 
information. 1589 
 1590 
Sarkans, U., Gostev, M., Athar, A., Behrangi, E., Melnichuk, O., Ali, A., et al. (2018). The BioStudies 1591 
database-one stop shop for all data supporting a life sciences study. Nucleic acids research 46, 1592 
D1266-D1270. DOI: 10.1093/nar/gkx965. 1593 
 1594 
Sato, T., Yuki, H., Ogura, K., and Honma, T. (2018). Construction of an integrated database for hERG 1595 
blocking small molecules. PloS one 13, e0199348-e0199348. DOI: 1596 
10.1371/journal.pone.0199348. 1597 
 1598 
Sauer, U.G., Deferme, L., Gribaldo, L., Hackermüller, J., Tralau, T., Van Ravenzwaay, B., et al. (2017). 1599 
The challenge of the application of 'omics technologies in chemicals risk assessment: 1600 
Background and outlook. Regulatory Toxicology and Pharmacology 91, S14-S26. DOI: 1601 
https://doi.org/10.1016/j.yrtph.2017.09.020. 1602 
 1603 
Schmidt, C.W. (2014). NTP nonneoplastic lesion atlas: a new tool for toxicologic pathology. 1604 
Environmental health perspectives 122, A76-A79. DOI: 10.1289/ehp.122-A76. 1605 
 1606 
Schreyer, A.M., and Blundell, T.L. (2013). CREDO: a structural interactomics database for drug 1607 
discovery. Database 2013, bat049-bat049. DOI: 10.1093/database/bat049. 1608 
 1609 
63 
 
Shameer, K., Glicksberg, B.S., Hodos, R., Johnson, K.W., Badgeley, M.A., Readhead, B., et al. (2018). 1610 
Systematic analyses of drugs and disease indications in RepurposeDB reveal pharmacological, 1611 
biological and epidemiological factors influencing drug repositioning. Brief Bioinform 19, 656-1612 
678. DOI: 10.1093/bib/bbw136. 1613 
 1614 
Shen, Q., Wang, G., Li, S., Liu, X., Lu, S., Chen, Z., et al. (2016). ASD v3.0: unraveling allosteric regulation 1615 
with structural mechanisms and biological networks. Nucleic Acids Research 44, D527-D535. 1616 
DOI: 10.1093/nar/gkv902. 1617 
 1618 
Silvester, N., Alako, B., Amid, C., Cerdeño-Tarrága, A., Clarke, L., Cleland, I., et al. (2018). The European 1619 
Nucleotide Archive in 2017. Nucleic Acids Research 46, D36-D40. DOI: 10.1093/nar/gkx1125. 1620 
 1621 
Sim, S.C., Altman, R.B., and Ingelman-Sundberg, M. (2011). Databases in the area of 1622 
pharmacogenetics. Human Mutation 32, 526-531. DOI: doi:10.1002/humu.21454. 1623 
 1624 
Singh, S.K., Malik, A., Firoz, A., and Jha, V. (2012). CDKD: a clinical database of kidney diseases. BMC 1625 
Nephrology 13, 23. DOI: 10.1186/1471-2369-13-23. 1626 
 1627 
Skuta, C., Popr, M., Muller, T., Jindrich, J., Kahle, M., Sedlak, D., et al. (2017). Probes &Drugs portal: an 1628 
interactive, open data resource for chemical biology. Nat Methods 14, 759-760. DOI: 1629 
10.1038/nmeth.4365. 1630 
 1631 
Smalter Hall, A., Shan, Y., Lushington, G., and Visvanathan, M. (2013). An overview of computational 1632 
life science databases & exchange formats of relevance to chemical biology research. 1633 
Combinatorial chemistry & high throughput screening 16, 189-198. DOI: 1634 
10.2174/1386207311316030004. 1635 
 1636 
Smirnov, P., Kofia, V., Maru, A., Freeman, M., Ho, C., El-Hachem, N., et al. (2018). PharmacoDB: an 1637 
integrative database for mining in vitro anticancer drug screening studies. Nucleic Acids 1638 
Research 46, D994-D1002. DOI: 10.1093/nar/gkx911. 1639 
 1640 
Spjuth, O., Rydberg, P., Willighagen, E.L., Evelo, C.T., and Jeliazkova, N. (2016). XMetDB: an open 1641 
access database for xenobiotic metabolism. Journal of Cheminformatics 8, 47. DOI: 1642 
10.1186/s13321-016-0161-3. 1643 
 1644 
Steger-Hartmann, T., Pognan, F., Sanz, F., and Diaz, C.A. (2009). In silico prediction of in vivo toxicities 1645 
(eTox)—The Innovative Medicines Initiative Approach. Toxicology Letters 189, S258. DOI: 1646 
https://doi.org/10.1016/j.toxlet.2009.06.374. 1647 
 1648 
Sterling, T., and Irwin, J.J. (2015). ZINC 15 – Ligand Discovery for Everyone. Journal of Chemical 1649 
Information and Modeling 55, 2324-2337. DOI: 10.1021/acs.jcim.5b00559. 1650 
 1651 
Stranger, B.E., Brigham, L.E., Hasz, R., Hunter, M., Johns, C., et al. (2017). Enhancing GTEx by bridging 1652 
the gaps between genotype, gene expression, and disease. Nature Genetics 49, 1664. DOI: 1653 
10.1038/ng.3969. 1654 
64 
 
Sud, M., Fahy, E., Cotter, D., Azam, K., Vadivelu, I., Burant, C., et al. (2016). Metabolomics Workbench: 1655 
An international repository for metabolomics data and metadata, metabolite standards, 1656 
protocols, tutorials and training, and analysis tools. Nucleic acids research 44, D463-D470. 1657 
DOI: 10.1093/nar/gkv1042. 1658 
 1659 
Sugita, T., Sasaki, S., Tanaka, K., Toda, M., Uneyama, C., Yamamoto, M., et al. (2006). [Development of 1660 
the databases for ADI (acceptable daily intake) and relevant information on food additives, 1661 
pesticides and veterinary drugs]. Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku, 69-73. 1662 
 1663 
Sushko, I., Novotarskyi, S., Korner, R., Pandey, A.K., Rupp, M., Teetz, W., et al. (2011). Online chemical 1664 
modeling environment (OCHEM): web platform for data storage, model development and 1665 
publishing of chemical information. J Comput Aided Mol Des 25, 533-554. DOI: 1666 
10.1007/s10822-011-9440-2. 1667 
 1668 
Sushko, I., Salmina, E., Potemkin, V.A., Poda, G., and Tetko, I.V. (2012). ToxAlerts: a Web server of 1669 
structural alerts for toxic chemicals and compounds with potential adverse reactions. J Chem 1670 
Inf Model 52, 2310-2316. DOI: 10.1021/ci300245q. 1671 
 1672 
The ENCODE Project Consortium (2011). A User's Guide to the Encyclopedia of DNA Elements 1673 
(ENCODE). PLOS Biology 9, e1001046. DOI: 10.1371/journal.pbio.1001046. 1674 
 1675 
Theodoropoulou, M.C., Bagos, P.G., Spyropoulos, I.C., and Hamodrakas, S.J. (2008). gpDB: a database 1676 
of GPCRs, G-proteins, effectors and their interactions. Bioinformatics 24, 1471-1472. DOI: 1677 
10.1093/bioinformatics/btn206. 1678 
 1679 
Toropov, A.A., Toropova, A.P., Raska, I., Leszczynska, D., and Leszczynski, J. (2014). Comprehension of 1680 
drug toxicity: Software and databases. Computers in Biology and Medicine 45, 20-25. DOI: 1681 
https://doi.org/10.1016/j.compbiomed.2013.11.013. 1682 
 1683 
Tym, J.E., Mitsopoulos, C., Coker, E.A., Razaz, P., Schierz, A.C., Antolin, A.A., et al. (2016). canSAR: an 1684 
updated cancer research and drug discovery knowledgebase. Nucleic Acids Research 44, 1685 
D938-D943. DOI: 10.1093/nar/gkv1030. 1686 
 1687 
Uhlen, M., Oksvold, P., Fagerberg, L., Lundberg, E., Jonasson, K., Forsberg, M., et al. (2010). Towards a 1688 
knowledge-based Human Protein Atlas. Nature Biotechnology 28, 1248. DOI: 1689 
10.1038/nbt1210-1248 https://www.nature.com/articles/nbt1210-1248#supplementary-1690 
information. 1691 
 1692 
Ursu, O., Holmes, J., Knockel, J., Bologa, C.G., Yang, J.J., Mathias, S.L., et al. (2017). DrugCentral: online 1693 
drug compendium. Nucleic acids research 45, D932-D939. DOI: 10.1093/nar/gkw993. 1694 
 1695 
Varadi, M., and Tompa, P. (2015). The Protein Ensemble Database. Adv Exp Med Biol 870, 335-349. 1696 
DOI: 10.1007/978-3-319-20164-1_11. 1697 
 1698 
65 
 
Veres, D.V., Gyurkó, D.M., Thaler, B., Szalay, K.Z., Fazekas, D., Korcsmáros, T., et al. (2015). ComPPI: a 1699 
cellular compartment-specific database for protein–protein interaction network analysis. 1700 
Nucleic Acids Research 43, D485-D493. DOI: 10.1093/nar/gku1007. 1701 
 1702 
Vinken, M., Knapen, D., Vergauwen, L., Hengstler, J.G., Angrish, M., and Whelan, M. (2017). Adverse 1703 
outcome pathways: a concise introduction for toxicologists. Archives of Toxicology 91, 3697-1704 
3707. DOI: 10.1007/s00204-017-2020-z. 1705 
 1706 
Von Eichborn, J., Murgueitio, M.S., Dunkel, M., Koerner, S., Bourne, P.E., and Preissner, R. (2011). 1707 
PROMISCUOUS: a database for network-based drug-repositioning. Nucleic Acids Res 39, 1708 
D1060-1066. DOI: 10.1093/nar/gkq1037. 1709 
 1710 
Weinstein, J.N., Collisson, E.A., Mills, G.B., Shaw, K.R., Ozenberger, B.A., Ellrott, K., et al. (2013). The 1711 
Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 45, 1113-1120. DOI: 1712 
10.1038/ng.2764. 1713 
 1714 
Wilks, C., Cline, M.S., Weiler, E., Diehkans, M., Craft, B., Martin, C., et al. (2014). The Cancer Genomics 1715 
Hub (CGHub): overcoming cancer through the power of torrential data. Database : the journal 1716 
of biological databases and curation 2014, bau093. DOI: 10.1093/database/bau093. 1717 
 1718 
Williams, A.J. (2008). Public chemical compound databases. Curr Opin Drug Discov Devel 11, 393-404. 1719 
 1720 
Wishart, D.S. (2014). Online Databases and Web Servers for Drug Metabolism Research. Wiley-VCH. 1721 
 1722 
Wishart, D.S., Feunang, Y.D., Marcu, A., Guo, A.C., Liang, K., Vázquez-Fresno, R., et al. (2017). HMDB 1723 
4.0: the human metabolome database for 2018. Nucleic Acids Research 46, D608-D617. DOI: 1724 
10.1093/nar/gkx1089 %J Nucleic Acids Research. 1725 
 1726 
Wishart, D.S., Knox, C., Guo, A.C., Cheng, D., Shrivastava, S., Tzur, D., et al. (2008). DrugBank: a 1727 
knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 36, D901-906. DOI: 1728 
10.1093/nar/gkm958. 1729 
 1730 
Wooden, B., Goossens, N., Hoshida, Y., and Friedman, S.L. (2017). Using Big Data to Discover 1731 
Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases. Gastroenterology 152, 1732 
53-67.e53. DOI: 10.1053/j.gastro.2016.09.065. 1733 
 1734 
Wu, H., Huang, J., Zhong, Y., and Huang, Q. (2017). DrugSig: A resource for computational drug 1735 
repositioning utilizing gene expression signatures. PLOS ONE 12, e0177743. DOI: 1736 
10.1371/journal.pone.0177743. 1737 
 1738 
Xenarios, I., Rice, D.W., Salwinski, L., Baron, M.K., Marcotte, E.M., and Eisenberg, D. (2000). DIP: the 1739 
database of interacting proteins. Nucleic acids research 28, 289-291. 1740 
 1741 
66 
 
Yang, W., Soares, J., Greninger, P., Edelman, E.J., Lightfoot, H., Forbes, S., et al. (2013). Genomics of 1742 
Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer 1743 
cells. Nucleic Acids Research 41, D955-D961. DOI: 10.1093/nar/gks1111. 1744 
 1745 
Yeung, C.K., Yoshida, K., Kusama, M., Zhang, H., Ragueneau-Majlessi, I., Argon, S., et al. (2015). Organ 1746 
Impairment-Drug-Drug Interaction Database: A Tool for Evaluating the Impact of Renal or 1747 
Hepatic Impairment and Pharmacologic Inhibition on the Systemic Exposure of Drugs. CPT 1748 
Pharmacometrics Syst Pharmacol 4, 489-494. DOI: 10.1002/psp4.55. 1749 
 1750 
Young, R.R. (2002). Genetic toxicology: web resources. Toxicology 173, 103-121. DOI: 1751 
https://doi.org/10.1016/S0300-483X(02)00026-4. 1752 
 1753 
Zarin, D.A., Tse, T., Williams, R.J., Califf, R.M., and Ide, N.C. (2011). The ClinicalTrials.gov Results 1754 
Database — Update and Key Issues. New England Journal of Medicine 364, 852-860. DOI: 1755 
10.1056/NEJMsa1012065. 1756 
 1757 
Zhang, G., Zhang, Y., Ling, Y., and Jia, J. (2015). Web Resources for Pharmacogenomics. Genomics, 1758 
Proteomics & Bioinformatics 13, 51-54. DOI: https://doi.org/10.1016/j.gpb.2015.01.002. 1759 
 1760 
Zhang, Q., Yang, B., Chen, X., Xu, J., Mei, C., and Mao, Z. (2014). Renal Gene Expression Database 1761 
(RGED): a relational database of gene expression profiles in kidney disease. Database: The 1762 
Journal of Biological Databases and Curation 2014, bau092. DOI: 10.1093/database/bau092. 1763 
 1764 
Zou, D., Ma, L., Yu, J., and Zhang, Z. (2015). Biological Databases for Human Research. Genomics, 1765 
Proteomics & Bioinformatics 13, 55-63. DOI: https://doi.org/10.1016/j.gpb.2015.01.006. 1766 
 1767 
 
